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Abstract
The aim of this thesis was to analyse speciﬁc mechanisms by which thyroid hormones
(TH) control energy metabolism in mice. As an animal model, TRH-R1 knockout
(ko) mice were studied since these mice exhibit congenital hypothyroidism. The lack
of the thyrotropin-releasing hormone receptor type 1 (TRH-R1) causes a diminished
stimulation of pituitary thyrotrophs. This, in turn, leads to a reduced thyrotropin
stimulus causing decreased TH production in these mice. In order to distinguish be-
tween eﬀects due to the missing TRH-R1 and consequences of the hypothyroid state
of the animals, TRH-R1 ko mice that were rendered euthyroid by TH treatment were
included in all studies as well.
Hypothyroid TRH-R1 ko mice exhibited decreased body weight and food intake that
could be normalised upon TH treatment. This decrease in body weight is most likely
due to a 50 percent reduction in white adipose tissue in hypothyroid TRH-R1 ko
mice compared to wild type (WT) animals. That indeed the observed alterations
were caused by the low TH levels could be ﬁrmly established by including two other
mouse models of hypothyroidism in this study. Pax8 ko mice that are born without
a functional thyroid gland and WT mice rendered hypothyroid by treatment with
a goitrogenic agent showed a similar reduction in food intake, body weight, and fat
mass. Gene expression analysis in adipose tissue revealed a decrease in adipogenesis
and adipocyte diﬀerentiation that most likely contribute to the smaller fat depots.
Studies of the brown adipose tissue conﬁrmed the important role of this tissue in the
regulation of energy expenditure. The brown adipose tissue of hypothyroid TRH-R1
ko mice was found to be activated as demonstrated by increased transcript levels of
uncoupling protein 1. Consequently, a signiﬁcant increase in oxygen consumption was
detected in the hypothyroid TRH-R1 ko mice compared to euthyroid control animals.
A major adipocyte-derived hormone that plays a key role in regulating food intake
and energy expenditure is leptin. As very limited information is available about the
role of TH in regulating leptin expression in mice, hypothyroid animals were analysed
with respect to leptin expression. These studies indeed demonstrated a decrease in
leptin mRNA expression in white adipocytes along with reduced leptin protein levels
in the circulation. Moreover, in vitro experiments using mouse 3T3-L1 adipocytes
revealed an upregulation of leptin expression upon T3 treatment, another indication
that TH stimulate leptin expression in mouse adipocytes.
The analysis of the central thyroidal state of TRH-R1 ko mice demonstrated a signiﬁ-
cant decrease in the hypothalamic T3 and T4 content compared to euthyroid animals.
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Abstract
As distinct neurons in the hypothalamus are major targets of TH action, further
studies were undertaken in order to investigate whether central leptin signalling is
aﬀected under hypothyroid conditions, particularly since alterations in the expression
of the leptin receptor as well as signal transducers could be detected in the hypothy-
roid animals. For this purpose, hypothyroid TRH-R1 ko mice were crossed with
leptin-deﬁcient ob/ob mice and injected with recombinant leptin. In comparison to
the euthyroid and leptin-deﬁcient control animals, these TRH-R1/ob double knock-
out (dko) mice responded to leptin treatment with a diminished suppression of food
intake and reduced body weight loss. Analysis of the central leptin target, signal
transducer and activator of transcription 3 (Stat3), revealed a marked decrease in
Stat3 phosphorylation in response to leptin in the hypothyroid TRH-R1/ob dko mice
suggesting central leptin resistance under hypothyroid conditions. These changes, in
turn, are expected to aﬀect central circuits regulating body weight and food intake.
In summary, the studies presented in this thesis uncovered new targets of TH action,
thereby unraveling novel mechanisms by which TH inﬂuence energy metabolism.
iv
Kurzfassung
Im Rahmen dieser Arbeit sollte der Einﬂuss von Thyroidhormonen (TH) auf den Ener-
giemetabolismus in Mäusen untersucht werden. Als Tiermodell wurde in erster Linie
die TRH-R1 Knockout (KO) Maus verwendet, die durch eine zentrale Hypothyreose
charakterisiert ist. Durch das Fehlen des Thyreotropin-Releasing Hormon Rezeptors 1
(TRH-R1) bleibt die Stimulation der thyreotrophen Hypophysenzellen in diesen Mäu-
sen aus. Infolgedessen kommt es, bedingt durch einen erniedrigten Thyreotropin Stimu-
lus, zu einer verringerten Produktion an TH in der Schilddrüse. TRH-R1 KO Mäuse,
welche mit TH substituiert wurden und entsprechend normale TH-Konzentrationen
in der Zirkulation zeigten, wurden als Kontrollen eingesetzt. Somit war es möglich,
Eﬀekte, die durch das Fehlen des TRH-R1 bedingt sind, von denen zu unterscheiden,
die durch den hypothyroiden Status der Mäuse verursacht wurden. Darüber hinaus
wurden auch athyroide Pax8 KO Tiere sowie Wildtyp (WT)-Mäuse mit einer chemisch
induzierten Hypothyreose in die Untersuchungen einbezogen.
Hypothyroide Mäuse zeichneten sich im Vergleich zu WT-Tieren durch ein geringeres
Körpergewicht sowie eine verringerte Nahrungsaufnahme aus, die durch Substitution
mit TH wieder normalisiert werden konnte. Das geringere Körpergewicht wird ver-
mutlich primär durch einen 50 Prozent verminderten Anteil an weißen Fettgewebe
verursacht. Die Analyse der Genexpression im weißen Fettgewebe deutete auf eine
beeinträchtigte Adipogenese und Fettzelldiﬀerenzierung hin, die vermutlich die Bil-
dung kleinerer Fettdepots bedingen. Die Analyse des braunen Fettgewebes bestätigte
eine wichtige Funktion dieses Gewebes bei der Regulation des Energieverbrauchs. Das
braune Fettgewebe der hypothyroiden TRH-R1 KO Mäuse zeigte einen aktivierten
Zustand, welcher insbesondere anhand der stark erhöhten Transkriptspiegel des Un-
coupling Protein 1 deutlich wurde. Daraus ergab sich ebenfalls ein signiﬁkant erhöhter
Sauerstoﬀverbrauch in den hypothyroiden TRH-R1 KO Mäusen im Vergleich zu den
euthyroiden Kontrolltieren.
Ein wichtiges Hormon, welches in Fettzellen synthetisiert wird und eine zentrale Rol-
le bei der Regulation des Appetits sowie des Energieverbrauchs spielt, ist Leptin.
Da nur begrenzte Informationen zur TH-abhängigen Regulation der Leptinspiegel in
Mäusen vorlagen, wurden im Rahmen dieser Arbeit die Auswirkungen einer Hypo-
thyreose auf die Leptinexpression analysiert. Hypothyroide Mäuse zeigten in der Tat
eine stark reduzierte Leptin-mRNA-Expression im weißen Fettgewebe sowie geringere
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Serum-Leptinwerte. Auch in vitro Studien bestätigten eine TH-Abhängigkeit der Lep-
tinexpression. Die Behandlung von murinen 3T3-L1 Fettzellen mit dem aktiven Thy-
roidhormon T3 führte zu einer signiﬁkanten Erhöhung der Leptin-Transkriptspiegel.
Die Untersuchung des TH-Status im Gehirn der TRH-R1 KO Mäuse ergab eine si-
gniﬁkante Verringerung in den hypothalamischen T3- und T4-Konzentrationen im
Vergleich zu den euthyroiden Tieren. Da hypothalamische Neurone wichtige Zielzellen
von TH darstellen, wurde in weiteren Experimenten überprüft, ob der zentrale Leptin-
signalweg durch den hypothyroiden Status beeinträchtigt ist, zumal Veränderungen
in den Transkriptspiegeln von Leptin-Rezeptoren und nachgeschalteten Signalvermitt-
lern nachgewiesen werden konnten. Um das zentrale Ansprechen auf Leptin zu unter-
suchen, wurden TRH-R1 KO Mäuse mit Leptin-deﬁzienten ob/ob Mäusen verpaart.
Nach einer mehrtägigen Applikation von Leptin zeigten diese TRH-R1/ob Doppel-
knockout (DKO) Mäuse im Vergleich zu den euthyroiden ob/ob Tieren eine geringere
Hemmung der Nahrungsaufnahme und einen geringeren Verlust an Körpergewicht. Im
Hypothalamus der hypothyroiden TRH-R1/ob DKO Mäuse wurde nach einer intrape-
ritonealen Leptingabe eine geringere phospho-Stat3-Immunreaktivität detektiert, was
auf eine zentrale Leptinresistenz unter hypothyroiden Bedingungen schließen lässt
(Stat3 = signal transducer and activator of transcription 3).
Insgesamt haben die Untersuchungen im Rahmen dieser Doktorarbeit gezeigt, dass ein
hypothyroider Zustand in Mäusen nicht nur die Leptinproduktion beeinﬂusst, sondern
auch zu einer veränderten Prozessierung des Leptinsignals in hypothalamischen Schalt-
kreisen führt, die wiederum eine zentrale Rolle für die Regulation des Körpergewichts
und der Nahrungsaufnahme ausüben. Somit konnten neue Mechanismen aufgezeigt
werden, wie TH den Energiemetabolismus beeinﬂussen.
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Chapter 1
Introduction
1.1 Energy Metabolism
Living in an environment where palatable, high calorie food is easily available will
increase the risk of weight gain and obesity and consequently the risk of major health
problems such as heart disease, high blood pressure, and type 2 diabetes mellitus.
Epidemic obesity has become a big health issue especially in Western societies. In the
United States more than two-thirds of adults are considered overweight (body mass in-
dex, BMI > 25) or obese (BMI ≥ 30) according to the National Health and Nutrition
Examination Surveys obtained in 2007-2008 [1]. Today, all but one state have already
an obesity rate above 20 percent [2]. Similar alarming observations have been made
in Germany: according to the German Federal Statistical Oﬃce, more than half of
the adult population was overweight in 2009. Maintenance of body weight is achieved
by adjusting energy expenditure to the level of energy intake. The past decade has
provided remarkable insights into molecular mechanisms that control energy home-
ostasis and on how dysfunction of these regulatory circuits favours changes in body
weight.
The brain plays an important role in the regulation of energy homeostasis as it re-
ceives information about the peripheral energy stores and subsequently integrates this
information into metabolic responses. Various humoral signals produced in the adi-
pose tissue, the endocrine pancreas, and the gastrointestinal tract are involved in this
communication system (Fig. 1.1, left). One key metabolic signal is leptin, a hormone
mainly produced by fat cells [3]. Studies in rodents and humans have shown that
leptin circulates together with the pancreatic hormone insulin at levels proportional
to body fat content, thereby signalling a surplus or shortage of metabolic fuel [3–7].
In addition, other metabolic signals have been identiﬁed in recent years. Ghrelin, also
known as a “hunger hormone”, is secreted from the stomach just before meal onset
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Abbreviations:
ARC; arcuate nucleus, PVN; paraventricular nucleus, DMV; dorsal motor
nucleus of the vagus nerve, BBB; blood-brain barrier, CCK; cholecystokinin,
ME; median eminence, TRH; thyrotropin-releasing hormone, CRH; cortico-
tropin-releasing hormone, ACTH; adrenocorticotropic hormone, TSH; thyroid-
stimulating hormone, GC; glucocorticoids, TH; thyroid hormones, IML; interme-
diolateral column, PNS; parasympathetic nervous system, SNS; sympathetic
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Figure 1.1: Integration and processing of peripheral metabolic signals. Left: Af-
ferent metabolic signals, e.g., insulin, leptin, ghrelin, and CCK arise from the pancreas, fat
tissue, the stomach, and intestine, respectively. These metabolic signals are assessed by spe-
cialised brain circuits such as the hypothalamus or brainstem. Within the hypothalamus, the
peripheral inputs are integrated in the ARC. Signals that are integrated in the DMV of the
brainstem are conveyed through the vagus nerve that innervates most of the gastrointestinal
tract. Right: The hypothalamus responds to peripheral inputs by transmitting eﬀerent sig-
nals from the PVN that can alter the neuro-endocrine system and the autonomic nervous
system. Peripheral metabolic signals that are integrated by the DMV aﬀect PNS outﬂow.
Modulation of the synthesis of TH and GC together with an activation of the PNS and SNS
evoke alterations in energy homeostasis by aﬀecting the metabolism of tissues such as liver,
fat, heart and skeletal muscle.
and ghrelin serum levels drop abruptly thereafter [8]. One of the gut peptides, chole-
cystokinin (CCK), is released during feeding and acts as a postprandial satiety signal
[9, 10]. A major target of these humoral mediators is the central nervous system
(CNS) where neuronal receptors for these peptides are strongly expressed.
A brain area heavily involved in the integration of peripheral metabolic signals is the
hypothalamus, for which a critical role in the regulation of energy balance has been
demonstrated. Lesioning studies in rats in the late 1940s showed that damage to
the ventromedial hypothalamus results in hyperphagia and obesity, whereas bilateral
lesions of the lateral hypothalamic area causes anorexia and weight loss [11]. The
majority of cell bodies of hypothalamic neurons are localised in areas protected by
the blood-brain barrier (BBB). However, a portion of the hypothalamus lies outside
this barrier, enabling neurons to sense and respond directly to variations in circulat-
ing levels of energy signals. Especially, the axon terminals of neurons in the arcuate
nucleus (ARC) which is situated adjacent to the ﬂoor of the third ventricle are in
direct contact with circulating factors and express the respective neuronal receptors
2
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[12–14]. ARC neurons send eﬀerent projections to several upstream hypothalamic
nuclei including the paraventricular nucleus (PVN) [15, 16]. The PVN does not only
regulate the neuro-endocrine axes, but also inﬂuences the autonomic nervous system
(Fig. 1.1, right). In particular, neurons in the PVN secrete thyrotropin-releasing
hormone (TRH) and corticotropin-releasing hormone (CRH) which in turn act on
the pituitary and therefore indirectly aﬀect energy metabolism by inﬂuencing the
metabolic rate, feeding behaviour, and body weight [16–20]. Other neuronal subpop-
ulations in the PVN have projections to motor neurons of the sympathetic (SNS)
and parasympathetic (PNS) nervous system. The sympathetic motor neurons arise
in the intermediolateral column (IML) in the spinal cord, whereas parasympathetic
motor neurons reside in the dorsal motor nucleus of the vagus nerve (DMV) in the
brainstem. Both divisions innervate diﬀerent organs such as liver, fat tissue, heart,
and skeletal muscle and regulate energy metabolism with opposing eﬀects. Whereas
the PNS promotes energy storage, the SNS increases energy expenditure primarily
through accelerating lipolysis and energy utilisation in fat tissue and skeletal muscle
[21]. Due to its major metabolic eﬀects, alterations in SNS activity are widely as-
sumed to promote the onset and development of obesity [22–24].
The caudal brainstem is also an important site for sensing and integrating energy
signals, particularly of those derived from the gut. Satiety information, transmitted
by so-called short-term signals such as CCK, is largely conveyed to the hindbrain’s
DMV by means of aﬀerent ﬁbers of the vagus nerve that innervates most of the gas-
trointestinal tract [25, 26]. Neurons of the DMV integrate short-term satiety signals
together with descending projections from the hypothalamus in order to regulate the
termination of a meal [27].
One of the most studied satiety signal that acts in the brain is the adipose tissue-
derived hormone leptin.
1.2 Leptin
With the discovery of spontaneously occurring hyperphagic and obese (ob/ob) mice
in 1949, the search for the gene causing this obese phenotype has begun and took
nearly 50 years [28, 29]. Elegant parabiosis experiments, performed by D. L. Cole-
man, then demonstrated that these obese mice lacked a circulating factor. In 1994,
J. M. Friedman and coworkers ﬁnally identiﬁed this factor as a hormone secreted by
the adipose tissue [3, 30, 31]. This protein, encoded by the ob gene, was named after
the Greek term "leptos" meaning thin. Substitution of ob/ob mice with recombinant
leptin resulted in a complete normalisation of body weight and food intake [32–34].
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Abbreviations:
ARC; arcuate nucleus, PVN; paraventricular nucleus, MC4R; melanocortin receptor 4,
Ob-R; leptin receptor, POMC; proopiomelanocortin, CART; cocaine and amphetam-
ine-related transcript, AgRP; agouti-related peptide, NPY; neuropeptide Y, GABA;
gamma aminobutyric acid, 3V; third ventricle, PM; plasma membrane, JAK2; Janus
kinase 2, Y; tyrosine, STAT3; signal transducer and activator of transcription 3,
SOCS3; suppressor of cytokine signalling 3, PTPN1; protein tyrosine phosphatase 1
-
-
Y705
+
+
GABA
Figure 1.2: Leptin action in ARC neurons and current model of leptin recep-
tor signalling. Left: In the ARC, leptin stimulates anorexigenic, appetite-repressing,
POMC/CART neurons and inhibits orexigenic, appetite-promoting, AgRP/NPY neurons.
These neurons innervate MC4R-expressing PVN neurons, thereby stimulating or repressing
melanocortin signalling, respectively. Activation of the melanocortin signalling pathway by
POMC/CART represses food intake and increases energy expenditure. Right: Leptin bind-
ing induces the JAK2/STAT3 pathway. Upon phosphorylation of receptor tyrosine residue
Y1138 by JAK2, the transcription factor STAT3 is recruited and phosphorylated at Y705.
STAT3 regulates gene expression of POMC, AgRP, and SOCS3. The regulators SOCS3 and
PTPN1 mediate a negative feedback by masking receptor residues or by dephosphorylating
JAK2.
The primary importance of leptin in the regulation of energy homeostasis has become
even more evident when congenital leptin-deﬁcient humans, who suﬀered from mor-
bid obesity, were identiﬁed [35]. In rodents and humans, leptin is almost exclusively
synthesised by adipose tissue and released into the blood stream where it circulates at
levels proportional to body fat mass [3, 5–7]. A main target site of leptin action is the
brain. Injection of recombinant leptin into brain ventricles in rodents have shown ef-
fective reduction in food intake and body weight and suggested central actions of this
adiposity signal in the regulation of energy metabolism [34, 36]. It has been demon-
strated that leptin acts mainly in the hypothalamus and brainstem to repress feeding
and to promote energy expenditure [37]. The best-characterised site of leptin action is
the hypothalamic ARC where it stimulates anorexigenic, appetite-repressing, proopi-
omelanocortin/cocaine and amphetamine-related transcript (POMC/CART) neurons
and inhibits orexigenic, appetite-promoting, agouti-related peptide/neuropeptide Y
(AgRP/NPY) neurons (Fig. 1.2, left). Activation of the melanocortin signalling
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pathway by the POMC-derived peptide α-melanocyte stimulating hormone (α-MSH)
promotes satiety and positive energy balance, whereas AgRP stimulates feeding by
antagonising the actions of α-MSH at speciﬁc melanocortin receptors [38, 39]. Ad-
ditionally, NPY/AgRP nerve terminals projecting to POMC neurons release the in-
hibitory neurotransmitter gamma aminobutyric acid (GABA), further conﬁrming the
inhibitory nature of these cells in the melanocortin system [40].
1.3 Leptin Signalling
Leptin’s eﬀects are mediated by interactions with the leptin receptor (Ob-R) which
belongs to the class-1 cytokine receptor family. At least ﬁve diﬀerent isoforms of the
leptin receptor exist in mice due to alternative splicing [41]. The major signalling recep-
tor isoform is the long-form Ob-Rb, whereas shorter and secreted isoforms (Ob-Ra,c-e)
might be involved in the transport of leptin or in the regulation of free leptin concen-
trations [42–45]. It has been shown that AgRP/NPY- as well as POMC-containing
neurons express the long-form Ob-Rb [37, 46, 47] and that deletion of Ob-Rb from
AgRP/NPY and/or POMC neurons results in weight gain [48, 49]. The major leptin
signalling pathway implicated in neural control of energy balance is the Janus kinase
2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway (Fig. 1.2,
right) [50–52]. In addition, in vitro and in vivo studies have shown that leptin also
stimulated insulin receptor substrate (IRS) phosphorylation [42], phosphatidylinosi-
tol 3-kinase (PI3K) activity [53–55], and mitogen-activated protein kinase (MAPK)
activity [42, 55], albeit their contribution to leptin’s anorexigenic action is still under
investigation.
Obese patients exhibit high circulating leptin concentrations. However, leptin fails
to adequately reduce food intake and promote weight loss in obesity, indicating a
state of leptin resistance. The underlying mechanisms of this reduced response to
high endogenous leptin are still poorly understood [56]. As one hypothesis, obese
patients may show a failure of circulating leptin to reach its targets in the brain. The
short-form Ob-Ra is highly expressed in the choroid plexus and microvessels and may
therefore play a role in leptin uptake or eﬄux from the cerebrospinal ﬂuid (CSF) and
in the receptor-mediated transport of leptin across the BBB into the brain [44, 45].
Indeed, leptin transport across the BBB has been shown to be impaired in obesity
[57]. Moreover, this impaired transport has been suggested to account in part for the
leptin-resistant state found in obesity. Alternatively, the intracellular leptin signalling
cascade may be inhibited. Indeed, potential roles for two inhibitors of leptin signalling,
the suppressor of cytokine signalling 3 (SOCS3) and the protein tyrosine phosphatase
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type 1 (PTPN1), have been suggested. SOCS3 which is induced by leptin can mask
phosphotyrosine residues on the Ob-Rb and on the catalytic region of JAK2, thus
preventing the activation of STAT3 [58–60]. Increased SOCS3 expression in several
rodent models of leptin-resistant obesity has been shown which is in line with the
concept of a negative-feedback regulator [61]. PTPN1 is supposed to interfere with
leptin signalling by the dephosphorylation of JAK2 [62–64]. PTPN1 expression is
found in the hypothalamus and PTPN1 levels are known to be increased during high-
fat diet induced leptin resistance [65]. Both, leptin-dependent and leptin-independent
mechanisms have been suggested to regulate hypothalamic PTPN1 expression.
In addition to leptin, other hormones are critically involved in the regulation of energy
metabolism. Thyroid hormones play a pivotal role in energy homeostasis due to their
functions in glucose and lipid metabolism, thermogenesis, and feeding behaviour.
1.4 Thyroid Hormones
The thyroid hormones (TH) 3,5,3’,5’-tetraiodothyronine (T4) and 3,3’,5-triiodothyro-
nine (T3) are only produced by follicular cells of the thyroid gland [66]. Iodide up-
take into follicular cells is facilitated through the sodium-iodide symporter (NIS) [67].
Upon translocation into the follicular lumen (colloid) and oxidation by the thyroid
peroxidase (TPO), iodine is incorporated into tyrosine residues of the glycoprotein thy-
roglobulin (Tg) [68]. This reaction results in either mono-iodinated or di-iodinated
tyrosine residues that are enzymatically coupled to produce T4 and T3 derivatives of
the Tg molecule. Proteolytical cleavage of Tg by lysosomal enzymes releases free T4
and T3 into the capillary system surrounding the follicles [69, 70].
Synthesis and secretion of TH are tightly controlled by factors released from the hy-
pothalamus, pituitary, and thyroid gland, also known as the hypothalamic-pituitary-
thyroid (HPT) axis (Fig. 1.3, left). The thyrotropin-releasing hormone (TRH), a
modiﬁed three amino acid peptide hormone (pyroGlu-His-Pro-NH2), is released from
hypothalamic PVN neurons [71, 72]. In mice, only neurosecretory neurons of the
medial parvocellular part of the PVN, so-called hypophysiotropic TRH neurons, re-
lease TRH that controls the HPT axis [73]. It is subsequently transported by the
portal blood system to the thyrotrophic cells of the anterior pituitary and stimulates
production and release of thyroid-stimulating hormone (thyrotropin, TSH). The thy-
rotrophic cells express the TRH receptor type 1 (TRH-R1), the only TRH receptor
localised in the pituitary [74]. Once TSH is released into the systemic circulation via
the cavernous sinuses, it stimulates the synthesis and release of T3 and T4 from the
thyroid gland. The amount of secreted TRH and TSH is negatively inﬂuenced by T3
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Figure 1.3: Regulation of the hypothalamic-pituitary-thyroid (HPT) axis and
action of iodothyronine deiodinases. Left: The thyrotropin-releasing hormone (TRH)
is secreted from paraventricular hypothalamic nucleus (PVN) neurons and transported to
the anterior pituitary to stimulate the synthesis and release of thyrotropin (TSH). Binding
of thyrotropin to TSH receptors on the surface of thyroid follicle cells induces the produc-
tion and release of thyroid hormones, with T4 being the predominant secreted hormone.
The expression of TRH and TSH is controlled by thyroid hormones via a negative feedback
loop at the level of the hypothalamus and pituitary, respectively. Right: Since T3 is the
receptor-activating thyroid hormone, T4 has to be converted by the action of deiodinating
enzymes. Both outer-ring deiodinases, DIO1 and DIO2, catalyse the bioactivation of T4 to
T3, or generate T2 from reverse T3 (rT3). DIO1 can also act as an inner-ring deiodinase,
thereby inactivating T4 to rT3. DIO3 inactivates T4 to rT3 and T3 to T2 by inner-ring
deiodination.
concentration at the level of the hypothalamus and pituitary, respectively [71, 75–77].
Consequently, high circulating TH levels suppress TRH and TSH transcription and,
vice versa, decreasing TH levels stimulate their transcription.
The major product released from the thyroid gland is the pro-hormone T4 that must
be converted to T3 in order to exert its biological activity. The activation and inacti-
vation of TH are mediated by diﬀerent types of deiodinases (Fig. 1.3, right). The type
1 deiodinase (DIO1) is predominantly expressed on the plasma membrane of liver and
kidney cells with its active center facing the cytosol [78–80]. Its expression is strongly
induced by T3. DIO1 does not only act as an outer-ring deiodinase converting T4 to
T3 or reverse T3 (rT3) to diiodothyronine (T2), but it can also deiodinate the inner
ring of T4, thereby converting T4 to rT3 [81]. Its major function, however, is to pro-
duce T3 that in turn is released into the circulation. In contrast to DIO1, deiodinase
type 2 (DIO2) exerts only outer-ring deiodinase activity and is believed to be an im-
portant regulator of the T3 content in the brain, pituitary, brown adipose tissue, and
skeletal muscle where DIO2 is mainly expressed [80, 82, 83]. TH activation in the hy-
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pothalamus and anterior pituitary by DIO2 promotes feedback regulation of the HPT
axis and is thus critical for the regulation of TRH and TSH expression [84]. There
is compelling evidence that DIO2 expression is regulated by transcriptional (cAMP
and TH), posttranscriptional (alternative splicing) and posttranslational (ubiquiti-
nation/deubiquitination) mechanisms [80, 85, 86]. At the transcriptional level, DIO2
expression is downregulated by its end product T3, whereas its substrate, T4, controls
enzyme activity at a posttranslational level. Deiodinase type 3 (DIO3) terminates lo-
cal TH action by the conversion of T4 to rT3 and T3 to T2 by inner-ring deiodination.
Due to its high expression in the neonatal brain, uterus, and placenta, DIO3 has been
suggested to play primarily a protective role during development [87].
1.5 Thyroid Hormone Signalling
The genomic actions of TH are mediated by its nuclear receptors. These thyroid
hormone receptors (TRs) constitutively bind as ligand-dependent transcription factors
to thyroid hormone responsive elements (TREs) located in the promoter of T3 target
genes [88, 89]. Gene regulation by TRs occurs both in the presence and in the absence
of the ligand. Whereas the T3-bound TR (holoreceptor) stimulates genes that are
positively regulated by T3, the unliganded TR (apo-receptor) represses those genes.
Conversely, negatively T3-regulated genes are generally activated by the apo-receptor
and repressed by the TR-T3 complex. TRs are encoded by two diﬀerent genes, the
TRα gene and the TRβ gene, which are located on diﬀerent chromosomes. Due to
alternative splicing and promoter usage, several TR isoforms exist with TRα1, TRβ1,
and TRβ2 being the major T3-binding receptors [90]. The various TR isoforms and
their diﬀerent tissue distributions provide a big diversity in the T3-mediated gene
regulation. The high expression of TRα1 in the heart, skeletal muscle, brain, and
brown adipose tissue revealed a potential role of this TR subtype in the regulation
of heart rate and proper thermogenesis besides other metabolic eﬀects. Accordingly,
studies in TRα1 knockout mice demonstrated a decrease in basal heart rate and a
0.5◦C reduction in body temperature [91]. TRβ1 is preferentially expressed in the
kidney and liver, whereas TRβ2 is found in the pituitary gland and in discrete areas
of the hypothalamus. Mice that are completely deﬁcient in the TRβ gene exhibit
a resistance to thyroid hormone (RTH) at the level of the HPT axis. These TRβ
knockout mice are characterised by elevated circulating TH concentrations and non-
suppressed TSH levels. Studies of mice lacking speciﬁcally TRβ2 identiﬁed this TR
subtype as the major regulator of the negative feedback of the HPT axis. Moreover,
studies using TR subtype knockout mice revealed a functional role for TRβ in the
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regulation of the auditory and vision system as well as in the control of cholesterol
metabolism. In addition to the transcriptional eﬀects, non-genomic actions of both
T4 and T3 have been suggested to contribute to some of the biological eﬀects of TH
[92].
1.6 Importance of Thyroid Hormones for Energy
Metabolism
Not surprisingly, signiﬁcant metabolic changes are observed in humans with alter-
ations in their thyroid status. An excess of TH increases endogenous glucose produc-
tion, lipid oxidation and is associated with higher energy expenditure and weight loss,
despite an increase in caloric intake [93, 94]. Although most of these parameters are
reversed in TH deﬁciency, studies in rodents and humans have suggested that hypothy-
roidism does not represent the complete mirror image of hyperthyroidism [95–97].
Key enzymes of energy metabolism are regulated by TH in peripheral tissues such as
skeletal muscle, liver, and adipose tissue. The consequence of TH action in these
tissues is an accelerated metabolic rate [98]. With regard to whole-body energy
metabolism, a key role for TH in brown adipose tissue (BAT) has been identiﬁed
[99]. BAT is the primary site of adaptive thermogenesis in small rodents and human
newborns [100]. Recent work has identiﬁed a signiﬁcant amount of BAT also in adult
humans where it appears to be regulated in the same manner as in mice [101–104].
In response to low ambient temperature or overfeeding, brown adipocytes respond
with an increased expression and activation of uncoupling protein 1 (UCP1), an inner
mitochondrial membrane protein that uncouples oxidative phosphorylation from ATP
synthesis. As a result, energy is dissipated as heat. This adaptive response is regu-
lated by various factors, including norepinephrine and TH [99, 105]. Cold-induced
thermogenesis depends on the synergism between adrenergic signalling and TH [106–
109] and the conversion of T4 to T3 by DIO2, along with T3-induced stimulation
of UCP1 expression [110–112]. As one example, mice with targeted disruption of
the DIO2 gene have an impaired adaptive thermogenesis [113]. However, these mice
develop compensatory mechanisms in order to survive cold exposure. In contrast to
DIO2-deﬁcient mice, hypothyroid rats completely fail to increase BAT thermal pro-
duction and do not survive cold exposure [114].
In addition to the impact on the peripheral regulation of energy metabolism, TH ex-
ert central eﬀects on thermogenesis, metabolism, and feeding behaviour. Receptors
for TH are expressed in a large number of brain areas including the hippocampus,
cerebral cortex, cerebellum, and hypothalamus. Abundant TR expression has been
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Figure 1.4: Local T3 bioavailability in the arcuate nucleus (ARC). The type 2
deiodinase (DIO2)-expressing tanycytes and glial cells control local T3 content in the ARC,
a tissue that is mandatory for feeding regulation. T4 from the cerebrospinal ﬂuid (CSF)
in the third ventricle (3V) or from the blood circulation is taken up by these cells and
deiodinated to T3, the bioactive form. Subsequently, T3 is transported to target cells where
it binds to nuclear thyroid hormone receptors (TR), thereby altering gene expression. Some
of the ARC neurons have nerve endings in the median eminence (ME), a circumventricular
organ, where the blood-brain barrier is absent. Therefore ARC neurons can directly sense
the T3 in the circulation.
demonstrated in the rat and human mediobasal hypothalamus, including the ARC
and PVN [115–117]. ARC neurons have been suggested to be supplied with T3 that
is locally produced by DIO2 in ARC glial cells and tanycytes lining the third ventricle
wall (Fig. 1.4) [118–121]. Hypothyroidism results in an increased DIO2 mRNA ex-
pression in tanycytes localised closely to the ARC neurons suggesting a functional role
for TH in this nucleus [122]. The entry of TH from the periphery to the hypothala-
mus and into cells is facilitated by speciﬁc TH transporters such as the organic anion
transporting polypeptide 1C1 (OATP1C1) and the monocarboxylate transporter 8
(MCT8) that are located at the blood-brain barrier, blood-cerebrospinal ﬂuid barrier,
and on plasma membranes of neurons and glial cells [123]. Of note, axon terminals of
those ARC neurons that project to the median eminence, which is not fully protected
by the BBB, are able to sense directly circulating factors like TH [12].
More recently, it has become clear that energy metabolism is also aﬀected by central
T3 action. Application of T3 to the hypothalamic ventromedial nucleus (VMH) in rats
decreased AMP-activated protein kinase (AMPK) activity in this area and increased
sympathetic nervous system outﬂow, thereby stimulating BAT thermogenesis [124].
In line with this ﬁnding, an increase in plasma glucose and in endogenous glucose pro-
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duction after T3 application to the hypothalamic PVN has been demonstrated in rats
which was due to an enhanced autonomic nervous system outﬂow to the liver [125].
Several studies suggested a stimulatory eﬀect of central T3 on food intake supporting
previous observations of hyperthyroidism-induced hyperphagia [94, 126]. Upon T3
application to the VMH, food intake signiﬁcantly increased in rats as a consequence
of an enhanced hypothalamic AMPK activity [127, 128]. Moreover, a fasting-induced
raise in hypothalamic T3 has been shown to activate uncoupling protein 2 (UCP2)
in orexigenic (appetite-promoting) ARC neurons and subsequently resulted in an in-
creased rebound feeding [129]. All these data reveal a physiological role for TH in the
control of hypothalamic neuronal networks regulating energy metabolism.
1.7 Mouse Models to Study Thyroid Hormone
Action
To understand the molecular mechanisms of TH action, various animal models have
been generated. Animal models commonly used include Pax8 ko mice that exhibit
congenital hypothyroidism, mice with goitrogen-induced hypothyroidism, and TRH-
R1 ko mice with central hypothyroidism.
The Pax8 knockout Mouse Model
The Pax8 ko mouse is a model of congenital hypothyroidism caused by thyroid gland
dysgenesis. The paired-box gene 8 (Pax8) is a transcription factor characterised by a
128-amino acid DNA binding motif, the paired domain. Pax8 is expressed in embry-
onal tissues, in particular in the developing thyroid gland where it is required for the
development of the follicular cells in the thyroid [130]. In addition to its role in thyroid
gland development, Pax8 regulates the expression of thyroglobulin, thyroid peroxidase,
and the sodium-iodide symporter [131, 132]. Mice lacking Pax8 are unable to develop
a functional thyroid gland and to produce TH. Because of their athyroidism Pax8 ko
mice survive only up to postnatal day 21. However, early postnatal substitution with
TH rescues the Pax8 ko mice from death and allows them to develop normally. Once
the treatment with TH is stopped, the mutant mice become athyroid again.
Goitrogenic Treatment
Mice treated with goitrogenic agents represent models of a variable onset of hypothy-
roidism. Goitrogenic agents are substances that act by blocking the production of TH
from the thyroid gland. Commonly used substances to suppress thyroid function are
propylthiouracil [PTU], mercapto-methylimidazole [MMI]), and sodium or potassium
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perchlorate. The goitrogens PTU and MMI inhibit the thyroid peroxidase-catalysed
iodination of tyrosine residues in the thyroglobulin molecule. Sodium and potassium
perchlorate compete with iodide at the sodium-iodide symporter, thereby blocking the
uptake of iodide by thyroid follicular cells. One of the disadvantages using goitrogens
to induce hypothyroidism in mice is the long period of goitrogen treatment. Usually
the hypothyroidism develops after 2-3 months of treatment.
The TRH-R1 knockout Mouse Model
Mice lacking the thyrotropin-releasing hormone receptor type 1 (TRH-R1) exhibit
central hypothyroidism, a condition characterised by an insuﬃcient TSH secretion in
the presence of low TH levels. The synthesis and release of TSH are largely dependent
on the stimulation of pituitary thyrotrophs by hypothalamic TRH. However, only the
TRH-R1 is present in the anterior pituitary and responds to hypothalamic TRH,
thereby regulating the HPT axis. Consequently, in mice that lack a functional TRH-
R1, the TRH stimulation of TSH-secreting thyrotrophs is abolished. Accordingly, TH
synthesis and subsequently circulating TH concentrations are decreased in TRH-R1
ko mice. In addition to its localisation in the pituitary, TRH-R1 mRNA is highly
expressed in the neuroendocrine brain regions, the autonomic nervous system, and
the visceral brainstem regions where it might be involved in the signalling of extra-
hypothalamic TRH.
1.8 Aim of this Project
TH play an essential role in the control of energy metabolism by regulating gene
expression in peripheral tissues, e.g., liver, skeletal muscle, and fat. The clinical
picture of hyperthyroid patients is characterised by an accelerated metabolic rate,
high blood pressure, and an increased ATP turnover, thereby favouring weight loss
[93]. In addition to the action in peripheral tissues, TH are sensed by specialised
brain circuits such as the hypothalamus. This brain tissue is crucially important for
the control of food intake and energy expenditure by responding to peripheral energy
signals such as leptin, insulin, and ghrelin. Interestingly, paraventricular hypothalamic
TRH neurons that adjust the pituitary-thyroid axis and the outﬂow of the autonomic
nervous system are regulated by both TH and leptin [71, 133]. Fasting results in a
downregulation of TRH expression followed by a drop in serum TH levels, whereas
leptin administration reverses this eﬀect, indicating a strong dominant eﬀect on the
hypothalamus-pituitary-thyroid axis [134, 135]. Whether TH in turn aﬀect central
leptin signalling has not been suﬃciently addressed.
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The aim of this thesis is to study the TH-dependent alterations of the peripheral and
central energy metabolism in hypothyroid mice. The TRH-R1 knockout mice are
a valuable animal model of central hypothyroidism due to the absence of the TRH
receptor on pituitary thyrotrophs. As a consequence, the animals show reduced T4
and T3 concentrations in the circulation. The analysis of TRH-R1 ko mice aims
to focus on i) a detailed metabolic characterisation of these hypothyroid animals,
ii) a study on the inﬂuence of the thyroidal state on leptin production and iii) the
investigation of thyroid hormone eﬀects on the central leptin signalling pathway.
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Methods
2.1 Experimental Animals and Treatments
Animal procedures were approved by the animal welfare committee of the Thüringer
Landesamt für Lebensmittelsicherheit und Verbraucherschutz (TLLV Thüringen; Er-
furt, Germany). The mice were kept at ~22◦C on a 12-h light/12-h dark cycle and
provided with standard laboratory chow (2.98 kcal/g; Altromin Spezialfutter GmbH)
and tap water ad libitum. For all experiments, littermate male mutant and wild type
mice of 3-5 months of age (herein after referred to as "adult") were used.
The TRH-R1-deﬁcient mouse strain was generated by homologous recombination us-
ing a targeting vector, designed to replace exon 2, 3, 4, and part of exon 5 of the TRH-
R1 gene with the β-galactosidase gene and the neomycin-resistance gene [136]. The
mice had been backcrossed onto the C57BL/6J genetic background. C57BL/6J ob/ob
mice were obtained from the Jackson Laboratory (Bar Harbor, USA). TRH-R1/ob
double knockout mice (herein after referred to as "R1/ob dko") were generated by in-
tercrossing these animals. Pax8 ko mice were generated by homologous recombination,
by replacing exon 2 of the Pax8 gene with a neomycin cassette [130]. C57BL/6N Pax8
heterozygous mice were kindly provided by A. Mansouri and P. Gruss (Göttingen, Ger-
many). Pax8 mice used in this study are from a mixed background between C57BL/6
and NMRI. Pax8 ko mice do not develop thyroid follicular structures and thus miss
a functional thyroid gland. They are, therefore, completely athyroid in postnatal life
and die around weaning unless they are substituted with thyroid hormones. Trans-
genic mice expressing EGFP under the control of the TRH-R1 promoter, so called
EGFP-R1 mice were generated using a modiﬁed bacterial artiﬁcial chromosome and
obtained from the Mutant Mouse Regional Resource Center (Davis, USA). The mice
were crossed onto the C57BL/6J genetic background. The genotype of animals used
in this study was determined by standard PCR analysis (35 cycles, 30 sec 94◦C, 1
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Gene Sequence (5′ → 3′) Annealing Restriction
TRH-R1
1: ACAGTGCTGTTGAAGCATCTG
61◦C /2: GACTGTCCTGGCCGTAACCGA
3: ATGAGTGTGGCTTGATTGGAA
Pax8
1: GGATGTGGAATGTGTGCGAGG
59◦C /2: GCTAAGAGAAGGTGGATGAGA
3: GATGCTGCCAGTCTCGTA
ob/ob 1: TGTAGATGGACCAGACTC 60◦C DdeI
2: ACTGGTCTGAGGCAGGGAGCA
EGFP-R1 1: CAGACAGAAAGGTGAAGGCTGGAA 60◦C /
2: TAGCGGCTCAGGCACTGCA
Table 2.1: Primers used for determining the genotype of mutant mice.
min annealing temperature, 30 sec 72◦C) with the primers indicated in table 2.1. For
the genotyping of ob/ob mice, the ampliﬁed PCR fragment was digested using the
restriction enzyme DdeI in order to detect the point mutation in the ob gene.
Hypothyroid TRH-R1 ko and R1/ob dko mice at the age of 3-4 weeks were rendered
euthyroid by supplementing the drinking water with thyroid hormones (TRH-R1 ko:
4 ng/ml T3 and 120 ng/ml T4; R1/ob dko: 4 ng/ml T3 and 60 ng/ml T4; Sigma)
and 0.01% BSA.
To ensure a normal development, athyroid Pax8 ko animals were daily injected with
T4 (sc, 20 ng/g bw) from postnatal day 0 until day 21. Afterwards, these animals
received thyroid hormone-supplemented drinking water (4 ng/ml T3, 120 ng/ml T4,
and 0.01% BSA) for 2 weeks. Then, the treatment was terminated in order to render
the animals athyroid.
C57BL/6J wild type and ob/ob mice were rendered hypothyroid at the age of 8
weeks by providing them with drinking water supplemented with 0.02% 2-mercapto-1-
methylimidazole (MMI), 1% sodium perchlorate, and 0.3% saccharin until serum T3
and T4 levels were close to the detection limit.
Leptin-deﬁcient (ob/ob and R1/ob dko) mice and WT controls were injected twice
daily (9 am and 5 pm) with recombinant mouse leptin (ip, 2 μg/g bw; PeproTech) for
3 consecutive days and sacriﬁced 3 h after the last injection. Brains were collected for
in situ hybridisation and quantitative real-time PCR analysis. For determination of
the leptin-induced suppression of food intake and loss of body weight, animals were
ﬁrst adapted to the injection-induced stress by applying ip PBS for 5 days. After-
wards the animals were injected twice daily with leptin (ip, 2 μg/g bw) for 3 days.
For phospho-Stat3 immunohistochemistry, the mice received leptin (ip, 2 μg/g bw)
45 min before sacriﬁce.
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2.2 RNA Isolation, cDNA Synthesis, and
Quantitative Real-Time PCR
The dissected tissues designated for quantitative real-time PCR analysis were rapidly
frozen on dry ice and stored at -80◦C. The RNeasy Lipid Tissue Mini Kit (Qiagen)
was utilised to isolate total RNA from fat tissue and diﬀerentiated 3T3-L1 adipocytes
while for all other tissues, the NucleoSpin RNA II Kit (Machery-Nagel) was employed
according to the instructions of the manufacturers. After laser-capture microdissec-
tion (section 2.3), RNA from dissected tissues was isolated using the RNeasy Micro
Kit (Qiagen) and ampliﬁed by use of the MessageAmp II aRNA Ampliﬁcation Kit
(Ambion). Synthesis of cDNA was performed using the Transcriptor High Fidelity
cDNA Synthesis Kit (Roche). To exclude the presence of genomic DNA, one sam-
ple without reverse transcriptase was included as well. The quantitative real-time
PCR was performed using the iQ SYBR Green Supermix and the Multicolor Real-
Time PCR Detection System (Bio-Rad). At least 5 samples per genotype were used
for the analysis. For fat tissues (iBAT and eWAT), hypoxanthine guanine phospho-
ribosyltransferase (HPRT) was taken as a housekeeping gene for normalisation and
cyclophilin D (CycD) for brain tissues (hypothalamus and ARC). Quantiﬁcation was
performed using a standard curve. The following primer pairs were designed for am-
pliﬁcation and used at an annealing temperature of 55◦C:
Gene NCBI no Sequence (5′ → 3′) Size
ACCI XR_033425 for: GTCCCCAGGGATGAACCAATA
rev: GCCATGCTCAACCAAAGTAGC
132 bp
AgRP NM_007427 for: TGAGTTGTGTTCTGCTGTTG
rev: TGAGGCCATTCAGACTTAGA
124 bp
ATGL NM_001163689 for: TGCCTGCTGATTGCCATGAG
rev: CTGCAGACATTGGCCTGGAT
130 bp
CycD NM_026352 for: GCAAGGATGGCAAGGATTGA
rev: AGCAATTCTGCCTGGATAGC
102 bp
DIO2 NM_010050 for: GGAACAGCTTCCTCCTAGAT
rev: GGTCTTCTCCGAGGCATAAT
119 bp
FAS NM_007988 for: GGAGGTGGTGATAGCCGGTAT
rev: TGGGTAATCCATAGAGCCCAG
140 bp
HPRT NM_013556 for: GCAGTACAGCCCCAAAATGG
rev: AACAAAGTCTGGCCTGTATCCAA
85 bp
HSL NM_001039507 for: CACCCATAGTCAAGAACCCCTTC
rev: TCTACCACTTTCAGCGTCACCG
175 bp
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Leptin NM_008493 for: CAGGGAGGAAAATGTGCTGGAG
rev: CCGACTGCGTGTGTGAAATGTC
162 bp
LPL NM_008509 for: AGGGCTCTGCCTGAGTTGTA
rev: AGAAATCTCGAAGGCCTGGT
199 bp
ME NM_008615 for: GAAAGAGGTGTTTGCCCATGA
rev: AATTGCAGCAACTCCTATGAGG
97 bp
Ob-R
(all isoforms)
NM_146146 for: ACAGTTCTGGCTGTCAATTC
rev: GTGTCCAGGAAAGGATGAC
142 bp
Ob-Ra NM_001122899 for: AAGTTGTTTTGGGACGATG
rev: ATTGGGTTCATCTGTAGTGG
119 bp
Ob-Rb NM_146146 for: GCACAAGGACTGAATTTCC
rev: GTTCAGGCTCCAGAAGAAG
100 bp
Ob-Rc NM_010704 for: CCTCTTGTGTCCTACTGCTC
rev: GTGACCTTTTGGAAATTCAG
127 bp
PGC-1a NR_027710 for: CAATGAATGCAGCGGTCTTA
rev: GTGTGAGGAGGGTCATCGTT
198 bp
POMC NM_008895 for: TTCAGACCTCCATAGATGTGTGG
rev: ATCTCCGTTGCCAGGAAACA
145 bp
PPAR-a NM_001113418 for: TCATACATGACATGGAGACCTTG
rev: ACTGGCAGCAGTGGAAGAATC
114 bp
PPAR-g NM_011146 for: TCGCTGATGCACTGCCTATG
rev: GAGAGGTCCACAGAGCTGATT
103 bp
PTPN1 NM_011201 for: CCAGTATTGGCCACAGCAAG
rev: AGTCAGGCCATGTGGTGTAG
179 bp
SOCS3 NM_007707 for: AGGGACCCCCTCCTTTTC
rev: AGAGAGGTCGGCTCAGTACCA
154 bp
UCP1 NM_009463 for: CGACTCAGTCCAAGAGTACTTCTCTTC
rev: GCCGGCTGAGATCTTGTTTC
73 bp
Table 2.2: Primers used for quantitative real-time PCR. The primers were designed
with the Clone manager software and synthesised by Euroﬁnes MWG Operon (Germany).
2.3 Laser-Capture Microdissection
The laser-capture microdissection (LCM) technique was used for the discrete dissec-
tion of hypothalamic ARC tissue in order to perform subsequently quantitative real-
time PCR analysis. The LCM was conducted in the laboratory of Prof. A. Habenicht
at the Friedrich-Schiller-Universität in Jena. Mice were sacriﬁced by CO2 inhalation
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and brains were dissected manually, frozen immediately in 2-methylbutane and stored
at -80◦C until cutting. Coronal brain sections (20 μm) were cut on a cryostat (Le-
ica CM 3050S). In the range of the hypothalamic ARC, 24 consecutive sections were
mounted on membrane slides (1.0 PEN; Carl Zeiss), stained with a 0.1% (w/v) cre-
syl violet acetate solution (dissolved in 70% ethanol; Sigma) for 5 min, dehydrated
by successive washing in 95% and 100% isopropanol, xylol, and dried on a heating
plate at 37◦C. ARC tissue was dissected using a LCM microscope (PALM; Carl Zeiss)
and laser energy of 70-80 mW. Microdissected samples were collected in nuclease-free
caps in TRIzol reagent (Invitrogen) and stored at 4◦C until RNA isolation (section
2.2). Quality control of total RNA was performed with the Agilent Bioanalyzer 2100
(Agilent Technologies). All solutions were made with autoclaved 0.1% DEPC water.
2.4 In Situ Hybridisation (ISH)
Dissected brains were immediately frozen in dry ice-cooled 2-methylbutane and stored
at -80◦C until cutting. Cryosections (20 μm, Leica CM 3050S) were obtained, thaw-
mounted on silane-treated slides, and stored at -80◦C until further processing. Brieﬂy,
sections were air-dried, followed by a 1-h ﬁxation in a 4% phosphate-buﬀered para-
formaldehyde (PFA) solution (pH 7.4) at room temperature (RT). After washing in
PBS, sections were permeabelised in 0.4% phosphate-buﬀered Triton X-100 for 10 min
and washed again in PBS and water. Acetylation was carried out by an incubation in
0.1 M triethanolamine (pH 8.0), containing 0.25% (v/v) acetic anhydrid, for 10 min.
After washing in PBS and water, sections were dehydrated in 50% and 70% ethanol
and air-dried.
RNA probes were generated by in vitro transcription in the presence of labeled nu-
cleotides (35S-UTP or DIG-11-UTP). As templates, cDNA plasmid subclones were
used as listed below (table 2.3).
For the synthesis of radioactively labeled probes, linearised cDNA templates (1 μg)
were transcribed in a ﬁnal reaction volume of 10 μl containing 1x RNA polymerase
reaction buﬀer with DTT (NEB), 5.55 MBq 35S-UTP (Hartmann Analytic), 1 mM
rNTPs (without UTP), 20 U RNase inhibitor (Promega), and 20-50 U RNA poly-
merase (Sp6, T3, or T7; NEB) for 1.5 h at 40◦C for Sp6 and 37◦C for T3 and T7. After
treatment with 10 U RNase-free DNase (Roche) for 15 min at 37◦C, the labeled ribo-
probes were separated from unincorporated nucleotides by spin-column chromatogra-
phy (GE Healthcare) and afterwards diluted in hybridisation buﬀer (50% formamide,
10% dextrane sulfate, 0.6 M NaCl, 10 mM Tris-HCl pH 7.5, 1x Denhardt’s solution,
100 μg/ml sonicated salmon sperm DNA, 1 mM EDTA, and 0.5 mg/ml t-RNA) to a
18
2.4 In Situ Hybridisation
cDNA Vector Fragment NCBI no Linear-
isation
RNA Poly-
merase and
Orientation
AgRP pGEM-Teasy nt 216-598 NM_007427 NotI
NcoI
T7 antisense
Sp6 sense
Ob-R (*)
(all isoforms)
pGEM-Teasy nt 1799-2437 NM_146146 PstI
SacII
T7 antisense
Sp6 sense
POMC pGEM-4 nt 56-526 J00759 XbaI
HindIII
T7 antisense
Sp6 sense
PTPN1 (*) pGEM-Teasy nt 679-1080 NM_011201 SpeI
SphI
T7 antisense
Sp6 sense
SOCS3 (*) pGEM-Teasy nt 1915-2427 NM_007707 SpeI
SacII
T7 antisense
Sp6 sense
TRH pLS nt 202-733 NM_009426 EcoRI
HindIII
T3 antisense
T7 sense
TRH-R1 pLS nt 577-1214 NM_013696 PstI
HindIII
T3 antisense
T7 sense
Table 2.3: Plasmids used for ISH. The plasmids were either generated during this study
(*) or they were generously provided by Dr. H. Heuer. The RNA polymerases Sp6, T3, or
T7 (NEB) were used as indicated. If not stated elsewhere, the probes were applied at a ﬁnal
concentration of 5x104 cpm/μl (35S-labeled) or 5 ng/μl (DIG-labeled).
ﬁnal concentration of 5x104 cpm/μl. Hybridisation was performed over night at 58◦C.
Next, slides were rinsed in 2x standard saline citrate (SSC), containing 0.3 M NaCl
and 0.03 M sodium citrate at pH 7.0, and then treated with RNase A (10 μg/ml;
Sigma) and RNase T1 (0.5 U/ml; Roche) for 30 min at 37◦C. After washing in 1x
SSC, 0.5x SSC, and 0.2x SSC for 20 min at RT each, slides were incubated for 1 h
in 0.2x SSC at 65◦C. The sections were washed in 0.2x SSC, dehydrated, and then
exposed to Biomax MR Film (Kodak) for 24-48 h. Subsequently, slides were dipped
in NTB2 autoradiographic emulsion (Kodak) and stored at 4◦C for 3-5 weeks, before
autoradiograms were developed in D19 (Kodak) for 5 min and ﬁxed in Rapid Fix
(Kodak) for 10 min. If required, sections were counterstained with a 1% (w/v) cresyl
violet acetate solution (Sigma) for 5 min and then photographed under darkﬁeld or
brightﬁeld illuminations using the microscope Olympus BH-2 and the camera Polaroid
DMC2.
Digoxigenin-labeled probes were synthesised according to the protocol for radioac-
tively labeled probes, but using a DIG RNA labeling Kit (Roche). RNA probes were
diluted in hybridisation buﬀer to a ﬁnal concentration of 5 ng/μl. Hybridisation
and post-hybridisation steps were carried out as described for radioactively labeled
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probes. Following the incubation in 0.2x SSC at 65◦C, sections were rinsed with
P1 (100 mM Tris, 150 mM NaCl, pH 7.5) and incubated in blocking solution (P1
containing 10% milk powder) for 1.5 h. The anti-digoxigenin antibody conjugated
with alkaline phosphatase (Roche) was applied at a dilution of 1:3000 over night at
4◦C. Tissue sections were rinsed with P1 and stained for 3-5 h in substrate solution
containing NBT (nitroblue tetrazolium chloride, 340 μg/ml; Biomol), X-phosphate
(5-bromo-4-chloro-3-indolyl-phosphate, 175 μg/ml; Biomol), 100 mM Tris-HCl, 100
mM NaCl, and 50 mM MgCl2, pH 9.5. For documentation, the microscope Olympus
BX-41 was used.
2.5 Immunohistochemistry (IHC) and Histology
Animals were anaesthetised by isoﬂurane and transcardially perfused with a 4%
phosphate-buﬀered PFA (pH 7.4) solution. The brains were removed carefully and
post-ﬁxed in the same ﬁxative over night at 4◦C. After a brief wash in PBS, brains
were cryoprotected in 30% phosphate-buﬀered sucrose for 3 days at 4◦C, washed in
PBS, frozen in methyl-butane and stored at -80◦C. Free-ﬂoating, coronal cryosections
(20 μm, Leica CM 3050S) were obtained and kept at 4◦C in PBS containing 0.02%
sodium azide until further use. Sections were carefully mounted on a positive-charged
microscope slide and air-dried, followed by a ﬁxation step in 4% phosphate-buﬀered
PFA (pH 7.4) for 5 min and a brief wash in PBS.
To visualise EGFP ﬂuorescence in EGFP-R1 reporter mice, cryosections were addi-
tionally ﬁxed with methanol/acetone (1:1) for 10 min and afterwards blocked with
5% normal goat serum (Invitrogen) in PBS for 1 h. Then, sections were incubated at
4◦C over night with rabbit anti-GFP (1:500; Invitrogen) and mouse anti-NeuN (1:500;
Millipore) antibodies in PBS containing 1% goat serum and DAPI (1:10000; Invitro-
gen). The slides were rinsed in PBS and secondary antibody incubation with Alexa
Fluor 488 goat anti-rabbit (1:1000; Invitrogen) and Alexa Fluor 555 goat anti-mouse
(1:1000; Invitrogen) was performed at RT for 1 h. After a brief wash with PBS, slides
were mounted in aqueous mounting medium (Sigma).
For phospho-Stat3 IHC, endogenous peroxidase was blocked by treating the sections
with 1% NaOH and 1% H2O2 in PBS for 20 min. Afterwards, sections were incubated
in 0.3% glycine and 0.03% SDS for 10 min each. Methanol/acetone (1:1) ﬁxation for
10 min was performed, before sections were blocked for 1 h with 3% normal goat serum
(in 0.2% Triton X-100 in PBS). P-STAT3 antibody (rabbit phospho-(Tyr705)-STAT3,
1:1000; Cell Signaling) was applied over night at 4◦C. After washing in PBS, a biotiny-
lated anti-rabbit antibody (1:200; Cell Signaling) was applied for 1 h at RT. The slides
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were subsequently developed using avidin-conjugated horseradish peroxidase (Vectas-
tain ABC Kit; Vector) with diaminobenzidine (DAB; Sigma) as a substrate according
to manufacturer’s instructions. Following development, the slides were dehydrated
and embedded in DePex mounting medium (Serva Electrophoresis).
Tissues used for histology were removed from animals sacriﬁced by CO2 inhalation
and ﬁxed in 4% formalin for 3 days at 4◦C. Then, tissues were rinsed in PBS, dehy-
drated in 30% and 50% ethanol, and embedded in paraﬃn. Serial 5 μm microtome
(Microm HM355S) sections were prepared and stained with hematoxylin and eosin
(H&E) according to a standard protocol. Sections were analysed with the microscope
Olympus AX-70.
2.6 Cell Culture
Murine 3T3-L1 preadipocytes were maintained in Alpha Minimum Essential Medium
(α-MEM; GIBCO) supplemented with 10% fetal bovine serum (FBS; GIBCO, Lot:
41F8201K) and 1x penicillin/streptomycin (PAA), with a change of medium every
3-4 days. For adipose diﬀerentiation, the cells were grown to conﬂuence. After 2
days, the cells were switched to diﬀerentiation medium containing 0.02 mg/ml insulin
(Sigma), 0.5 mM 3-isobutyl-1-methylxanthine (Sigma), and 1 μM dexamethasone
(Sigma). The cells remained in diﬀerentiation medium for 2 days before switching
to post-diﬀerentiation medium supplemented with insulin (0.02 mg/ml) for 14 days.
When cells had become fully diﬀerentiated (>90%), FBS was replaced by 0.1% bovine
serum albumin (BSA; Sigma) for 12 h, before the thyroid hormone T3 (50 nM) was
added. The incubation was continued for 6 h and 12 h, respectively. In the control
group, the medium was changed without adding T3. From 3 replicates, each, total
cellular RNA was obtained as described in section 2.2.
2.7 Serum and Tissue Parameter Measurements
Sera were collected and stored at -20◦C. Serum T4 and T3 levels were determined by
radioimmunoassay in the department of Prof. T. Visser at Erasmus Medical Center
in Rotterdam, the Netherlands, as previously described [137]. Determination of the
thyroid hormone content in tissues was carried out in the laboratory of Prof. V.
Darras at Katholieke Universitet in Leuven, Belgium, as previously described [138].
The tissues were rapidly frozen on dry ice and stored at -80◦C. The determination of
T4 and T3 levels were made on pooled hypothalami obtained from 5 adult animals
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or on pooled BAT lobes from 5 adult animals per group. Leptin concentration in
the serum was determined using a mouse Leptin Elisa Kit (Millipore) according to
manufacturer’s instructions.
2.8 Oxygen Consumption, Locomotor Activity,
and Fat Mass Determination
Oxygen consumption and locomotor activity were simultaneously determined using
the CLAM System (Comprehensive Laboratory Animal Monitoring System; Colum-
bus Instruments). The animals were ﬁrst adapted to the chambers for 24 h prior to
measurements. During the 24-h observation period, mice were given access to food
and water ad libitum. Oxygen consumption, determined by indirect calorimetry and
expressed as ml O2 consumed per minute, was normalised to body weight (in lean
mice to (kg)0.75 and in obese mice to (kg)0.67). The chambers’ sides were equipped
with a mouse sensor (16 beams of infrared) and spontaneous activity was assessed
by counting horizontal beam interruptions. Only when the animal traversed the cage
and a series of IR beams in sequence were broken, counts were scored. Repeated
interruptions of the same IR beam were ignored.
In vivo body composition of mice was determined using a micro-computed tomogra-
phy (micro-CT) scanner. The LaTheta LCT-100ATM Scanner (Zinsser Analytic) was
used. The system determines diﬀerences in X-ray density of adipose tissue, bone, air,
and the remainder and distinguishes visceral and subcutaneous fat based on the detec-
tion of the abdominal muscle layers. Adipose tissue weights were computed using the
common density factor of 0.92 g/cm3. Animals were scanned under deep anesthesia (5
μg/g midazolam, 0.5 μg/g medetomidine, and 2 μg/g fentanyl). Afterwards animals
were injected with an antidote solution (2.5 μg/g atipamezol, 0.5 μg/g ﬂumazenil, and
1.2 μg/g naloxon) in order to wake them up. Abdominal scans were obtained between
vertebrae L5 and L6. Weights of visceral and subcutaneous fat were normalised to
gram of total body weight.
2.9 Statistical Analysis
Data were analysed using the 2-tailed Student’s t-test and presented as their mean
value ± s.d. if not stated otherwise. Statistical diﬀerences that were considered
signiﬁcant are indicated as *P<0.05, **P<0.005, ***P<0.001.
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Chapter 3
Results
3.1 Generation and Metabolic Characterisation of
TRH-R1 ko Mice
3.1.1 Generation of TRH-R1 ko Mice
Homozygous thyrotropin-releasing hormone receptor 1-deﬁcient (TRH-R1 ko) mice
were generated by R. Rabeler et al. [136]. For the disruption of the TRH-R1 gene, a
targeting vector has been constructed to delete the entire coding region composed of
exons 2, 3, 4, and part of exon 5 (Fig. 3.1A). These exons were replaced by a LacZ/-
neomycin reporter cassette by homologous recombination. The resulting chimeric
mice were outcrossed to the C57BL/6 genetic background. In the oﬀspring, wild type
and targeted alleles were discriminated by PCR ampliﬁcation with a LacZ-speciﬁc
primer and two primers binding the endogenous gene sequence (Fig. 3.1B). Product
size for the targeted allele was obtained at 600 bp and for the endogenous allele at
925 bp.
3.1.2 Expression of TRH-R1 in the Mouse Brain
The BAC transgenic EGFP-R1 mouse (EGFP expression driven by the TRH-R1 pro-
moter) was used to visualise neurons in which the TRH-R1 promoter is active. For
this purpose, immunohistochemistry was performed using an anti-GFP antibody. In
order to discriminate between diﬀerent hypothalamic nuclei, co-staining with the neu-
ronal marker NeuN and the nuclei marker DAPI was performed. GFP-positive cell
bodies and axons were found in distinct compartments of the brain. Strong GFP
staining was detected in the central amygdaloid nucleus (Ce), lateral hypothalamus
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Endogenous (925 bp)
Targeted (600 bp)
GS-p (E,T) GS-p (E)
LacZ-p (T)
Targeting Vector
PGK-tk
H H
LacZ pA RSV-Neo pA
E S
1 kb
Wild type Allele
E SH H
ATG TAA
1 42 3 5
Targeted Allele
E SH H1 5
LacZ pA RSV-Neo pA
A
B
Wild type Allele
ATG
GS-p (E,T)
Targeted Allele
LacZ
Figure 3.1: Targeting strategy for TRH-R1 deletion. A) Exons are represented
by either stippled (untranslated regions), or black (open reading frame) boxes. The entire
coding region (exon 2 at the transcriptional start site ATG, as well as exon 3, 4, and part
of exon 5) of the TRH-R1 gene was replaced by the β-galactosidase gene LacZ and the
neomycin-resistance gene RSV-Neo. Abbreviations: H, HindIII; E, EcoRI; S, StuI; pA,
polyadenylation site; RSV-Neo, Rous sarcoma virus neomycin selection cassette; PGK-tk,
herpes simplex virus-thymidine kinase under the control of the pgk promoter. Illustration
modiﬁed from [136]. B) Homologous recombination was conﬁrmed by PCR analysis using
3 primers recognising the endogenous (E) or the targeted (T) allele. Abbreviations: GS-p,
gene-speciﬁc primer; LacZ-p, LacZ-speciﬁc primer.
(LH), dorsomedial hypothalamus (DMH), and medial amygdaloid nucleus (Me) (Fig.
3.2A). Weaker signals were detected in the paraventricular nucleus (PVN), anterior
hypothalamus (AH), cerebral cortex (CC), and arcuate nucleus (ARC). Higher mag-
niﬁcation revealed distinct neuronal staining in the AH, LH, and DMH, whereas the
PVN and ARC showed diﬀuse GFP staining patterns which is indicative for neuronal
projections (Fig. 3.2C).
In order to localise TRH-R1 mRNA-expressing cells in the mouse brain, radioactive
ISH was performed. The ISH analysis of TRH-R1 mRNA revealed hybridisation sig-
nals in the LH, CC, dentate gyrus (DG), DMH, ventromedial hypothalamus (VMH),
and Me (Fig. 3.2B and C). Within the DMH, particularly strong hybridisation sig-
nals were observed in the caudal region of the nucleus, whereas in the VMH, the
ventrolateral part showed highest signal intensities.
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Figure 3.2: Expression of TRH-R1 in the mouse brain. A) Immunohistochemical
staining of GFP alone, or in combination with NeuN and DAPI on 20 μm coronal cryosec-
tions of adult transgene mice expressing EGFP under the control of the TRH-R1 promoter.
The expression pattern is shown on brain sections ranging from the anterior to the posterior
hypothalamus. Scale bar represents 1 mm. B) TRH-R1 mRNA levels were assessed by ra-
dioactive ISH on 20 μm coronal brain sections of WT mice. Scale bar represents 1 mm. C)
Detailed view of hypothalamic TRH-R1 expression. Scale bar represents 200 μm.
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3.1.3 Serum Thyroid Hormone Levels
The activity of the hypothalamus-pituitary-thyroid (HPT) axis is disturbed in TRH-
R1 ko mice due to the lack of TRH-R1 expression in pituitary thyrotrophs. As a
consequence, TH production in the thyroid gland is diminished: total T4 and T3
serum levels were both reduced by a factor of approximately 2 compared to WT
controls (Fig. 3.3A). However, when the mutant mice were supplied with TH, they
could be rendered euthyroid and reached T4 and T3 values similar to WT mice. TH
were given via the drinking water as described in Methods, section 2.1. Due to the
low serum TH levels, the T3-driven suppression of TRH expression in the PVN of
the hypothalamus is downregulated. Accordingly, TRH expression, as determined by
radioactive ISH, was enhanced in hypothyroid TRH-R1 ko mice compared to WT
controls and normalised after TH treatment (Fig. 3.3B).
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Figure 3.3: Serum thyroid hormone concentrations and hypothalamic TRH
mRNA expression of adult (3-5 months) mice. A) Total T4 and total T3 levels
were determined in the serum of WT, TRH-R1 ko (R1ko), and of TRH-R1 ko mice that
were supplied with TH (R1ko+TH) via the drinking water (4 ng T3 and 120 ng T4 per ml
drinking water) starting from the time of weaning. TRH-R1 ko mice showed decreased T4
and T3 concentrations compared to WT control mice and were rendered euthyroid by TH
supply. Values are indicated as mean ± s.d. of >7 animals per group: ***P<0.001. B)
TRH mRNA expression in the PVN was assessed by radioactive ISH on 20 μm coronal brain
sections. As a consequence of the low T4 and T3 serum levels, TRH expression was markedly
increased in TRH-R1 ko mice. TH treatment of TRH-R1 ko mice led to a normalisation of
TRH expression. Scale bar represents 200 μm.
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3.1.4 Food Intake, Body Weight and Body Length
The initial metabolic characterisation of adult hypothyroid TRH-R1 ko mice revealed
a signiﬁcant decrease in daily food intake (16.9%) and in body weight (13.7%) com-
pared to WT controls (Fig. 3.4A and B). It has been demonstrated that the mutant
mice are born without any diﬀerences in body weight and that they develop normally
until the age of 16 d. Hereafter, around the time of weaning and up to the age of 12 wk,
TRH-R1 ko mice showed reduced growth compared to WT animals [136]. Remarkably,
treatment of the mutant mice with TH for 3 months (starting at weaning) normalised
the decreased food intake, but not completely the low body weight. Compared to
WT mice, the body weight of the euthyroid-rendered mutant mice was still decreased
by 8.9%. Analysis of the body length showed no diﬀerences between genotypes, sug-
gesting that the decreased body weight of the hypothyroid mutant mice cannot be
explained by growth retardation (Fig. 3.4C).
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Figure 3.4: Basal food intake, body weight, and length of mice kept on a regular
chow diet. Caloric intake (A), body weight (B), and body length (measured from nose to
anus) (C) of hypothyroid TRH-R1 ko mice, compared to WT and euthyroid-rendered TRH-
R1 ko mice. Caloric intake and body weight were decreased in TRH-R1 ko mice compared
to WT. TH treatment normalised caloric intake, but not body weight. No diﬀerences in body
length were noted between the diﬀerent genotypes. Data are presented as mean ± s.d. of >5
animals per group: *P<0.05, **P<0.005, n.s.; not signiﬁcant.
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3.1.5 Energy Expenditure
In order to investigate whether the central hypothyroidism of TRH-R1 ko mice aﬀects
energy metabolism, the metabolic rate was determined using the CLAM System. Oxy-
gen consumption was determined during a 24-h period and was found to be increased
by approximately 5-10% in hypothyroid TRH-R1 ko mice compared to WT controls
(Fig. 3.5A). No obvious changes were observed between the euthyroid-rendered mu-
tant mice and WT animals. Monitoring of the locomotor activity revealed no diﬀer-
ences between the genotypes indicating that the increase in oxygen consumption was
not due to an increased overall physical activity of the hypothyroid mutant mice (Fig.
3.5B).
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Figure 3.5: Determination of 24-h total oxygen consumption and physical activ-
ity in mice during a regular 12-h light/12-h dark cycle by the use of the CLAM
System. Animals (10-12 per group) were adjusted to the new environment for 24 h before
the measurement. Throughout the experiment, animals had free access to food and water.
The double-headed arrow indicates the dark phase of the light/dark cycle. Oxygen consump-
tion was measured by indirect calorimetry and normalised to the body weight (kg0.75). As
shown in A), only hypothyroid TRH-R1 ko animals exhibited increased oxygen consumption
compared to WT mice. B) Horizontal movements were assessed by counting light beam
breaks. However, no diﬀerences were observed between the diﬀerent animal groups. Data
are represented as mean ± s.e.m. of four time points with an interval of 15 min: *P<0.05,
#P<0.005.
28
3.2 Fat Metabolism of Hypothyroid TRH-R1 ko Mice
3.2 Fat Metabolism of Hypothyroid TRH-R1 ko
Mice
3.2.1 Brown Adipose Tissue Analysis
In search for the cause of the increased oxygen consumption in hypothyroid TRH-
R1 ko mice, the brown adipose tissue (BAT) was analysed with regard to tissue
morphology, gene expression proﬁle and local T3 content. In rodents, the BAT is
the main site of facultative thermogenesis and becomes activated by norepinephrine
in response to a cold environment in order to maintain body temperature. Heat is
generated by uncoupling the cellular metabolism from ATP synthesis via the induction
of uncoupling protein 1 (UCP1). Accordingly, the BAT is one of the major oxygen-
consuming organs in the body, especially during facultative thermogenesis. TH are
essential for the full thermogenic response of the BAT by sustaining the norepinephrine
signalling cascade [106, 108, 109] and regulating UCP1 gene expression [111, 112].
Especially T3 that is locally produced by the T4 activating enzyme deiodinase type
2 (DIO2) is important to saturate all TH receptors [110, 113].
The histological analysis of interscapular BAT (iBAT) sections stained with H&E
revealed a striking phenotype in TRH-R1 ko mice. The brown fat cells of these hy-
pothyroid mice contained much smaller lipid vacuoles than those of WT animals (Fig.
3.6). However, upon TH treatment these diﬀerences in BAT morphology disappeared.
The BAT of TH-treated TRH-R1 ko mice had a similar amount and size of lipid
droplets compared to WT animals. This observation indicated that in the BAT of
hypothyroid TRH-R1 mutant mice the metabolism is highly upregulated, a condition
which could be normalised by raising peripheral TH levels.
Figure 3.6: Interscapular brown adipose tissue (iBAT) morphology. Formalin-
ﬁxed paraﬃn sections (5 μm) of brown fat were stained with H&E. Brown adipocytes of
hypothyroid TRH-R1 ko mice contained smaller lipid vacuoles compared to WT controls.
Size of vacuoles increased in mutant mice after TH treatment. Scale bar represents 100 μm.
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Figure 3.7: Gene expression in iBAT as measured by real-time PCR. Relative
mRNA expression levels were determined in 5 animals per group and normalised to HPRT.
Expression of marker genes of facultative BAT thermogenesis (DIO2, UCP1, PGC-1a, and
PPAR-g) was signiﬁcantly upregulated in hypothyroid TRH-R1 ko mice and decreased after
TH treatment. Data are presented as mean ± s.e.m.: *P<0.05, **P<0.005, ***P<0.001.
Gene expression proﬁling was performed on iBAT and revealed a strong induction
of genes involved in thermogenesis in hypothyroid TRH-R1 ko mice. DIO2 gene
expression was increased 3.2-fold and this upregulation was paralleled by an induction
of UCP1 (2.4-fold), peroxisome proliferator-activated receptor gamma (PPAR-g; 1.6-
fold) and PPAR-g coactivator-1 alpha (PGC-1a; 2-fold) (Fig. 3.7). These striking
diﬀerences between TRH-R1 ko and WT mice disappeared when the mutant mice
were treated with TH. In contrast, gene expression of markers of lipogenesis such as
malic enzyme (ME), fatty acid synthase (FAS), or acetyl-CoA carboxylase I (ACCI)
and markers of lipolysis such as adipose triglyceride lipase (ATGL) and hormone-
sensitive lipase (HSL) were not signiﬁcantly aﬀected by the thyroidal state of the
animals.
The upregulation of DIO2 gene expression in the iBAT of TRH-R1 ko mice led to the
assumption of elevated tissue T3 levels. In order to test whether the thyroidal state
of the BAT of hypothyroid animals is aﬀected, tissue T3 levels were determined in
hypothyroid TRH-R1 ko mice and compared to WT animals and TH-treated mutant
mice. Indeed, the determination of the BAT T3 content revealed 33% higher T3
concentrations in hypothyroid TRH-R1 ko mice compared to WT controls (P=0.07)
and 78% higher T3 levels compared to euthyroid-rendered mutant mice (P<0.05) (Fig.
3.8). The results suggest that despite the low circulating TH concentrations in TRH-
R1 ko mice, the BAT contains elevated tissue T3 levels. It is tempting to speculate
that an increase in DIO2 activity in the BAT likely contributes to the increased T3
levels.
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Figure 3.8: Concentration of T3 in iBAT. T3 concentration was measured in BAT
lobes of 5 adult animals per group. TRH-R1 ko mice exhibited increased BAT T3 content
which declined after TH treatment. Data are presented as mean ± s.d.: *P<0.05.
3.2.2 White Adipose Tissue Analysis
The amount of white adipose tissue (WAT) in 5-6 months old mice was analysed by the
use of a micro-computed tomography (micro-CT) scanner. When normalised to the
corresponding body weights, hypothyroid TRH-R1 ko mice showed a 50% reduction
in visceral (vc) and a 38% reduction in subcutaneous (sc) white fat compared to WT
controls (Fig. 3.9), while the lean mass was not aﬀected (data not shown). Fat mass
normalised when the mutant mice were treated with TH between weaning time and
the time point of analysis.
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Figure 3.9: Determination of white fat mass. Visceral (vc) and subcutaneous (sc) fat
mass were determined between lumbar vertebra 5 and 6 using a micro-CT scanner. Data
were normalised to total body weight and are presented as mean ± s.d. of >9 animals per
group: **P<0.005, ***P<0.001. In hypothyroid TRH-R1 ko mice, both vc and sc fat mass
were signiﬁcantly decreased, but normalised when the animals were treated with TH.
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Figure 3.10: Epididymal white adipose tissue (eWAT) morphology. A) Formalin-
ﬁxed paraﬃn sections (5 μm) of white fat were stained with H&E. Scale bar represents 100
μm. B) The size of white adipocytes was quantiﬁed using ImageJ (n>5). No signiﬁcant
diﬀerences were noted between the diﬀerent animal groups.
A histological analysis of epididymal white adipose tissue (eWAT) sections and the
quantiﬁcation of the size of white adipocytes showed no signiﬁcant diﬀerences between
the genotypes (Fig. 3.10A and B). This indicates that rather the amount of white
adipocytes than the cell size determines fat mass in hypothyroid TRH-R1 ko mice.
To examine whether the adipose tissue phenotype was caused by an altered lipid
handling, the expression of gene products involved in lipid biosynthesis (ME, FAS,
and ACCI), lipid tissue diﬀerentiation (PPAR-g and PGC-1a), lipid uptake (lipopro-
tein lipase, LPL), and fatty acid utilisation/oxidation (HSL, ATGL, and PPAR-a)
was investigated. Expression proﬁling in the eWAT revealed evidence for decreased
lipogenesis in hypothyroid TRH-R1 ko mice: ME and ACCI mRNA expression levels
were reduced approximately by 2-fold whereas FAS expression showed even a decrease
of 6.7-fold compared to WT controls (Fig. 3.11). Moreover, the expression of gene
products involved in lipid tissue diﬀerentiation and lipid uptake were found to be
suppressed as well: PPAR-g and PGC-1a were approximately 3-fold and LPL 2-fold
decreased in TRH-R1 ko mice. These pronounced changes disappeared when the mu-
tant mice were rendered euthyroid. No signiﬁcant changes were seen in ATGL, HSL,
and PPAR-a mRNA expression.
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Figure 3.11: Gene expression in eWAT as measured by real-time PCR. Relative
mRNA expression levels were determined in >5 animals per group and normalised to HPRT.
Expression of marker genes involved in lipogenesis (ME, FAS, and ACCI), lipid tissue dif-
ferentiation (PPAR-g and PGC-1a), and lipid uptake (LPL) was decreased in TRH-R1 ko
mice compared to WT controls and normalised after TH treatment of the mutant mice. Data
are presented as mean ± s.d.: *P<0.05, **P<0.005, ***P<0.001.
In view of the substantial diﬀerences in WAT mass and lipid handling in TRH-R1 ko
mice, leptin production in these hypothyroid mice was analysed. For that purpose
leptin mRNA levels in WAT were analysed by quantitative real-time PCR and serum
leptin levels were determined by ELISA. Leptin is primarily produced by WAT and
blood leptin levels are directly proportional to body fat mass in men and mice [3, 5–
7]. In the eWAT of hypothyroid TRH-R1 ko mice, leptin expression was repressed
by 2-fold compared to WT controls and normalised in TH-treated mutant mice (Fig.
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Figure 3.12: Leptin mRNA expression in eWAT and leptin serum levels. A)
Relative gene expression of leptin in eWAT was measured by real-time PCR and normalised
to HPRT in >5 animals per group. B) Leptin levels in the serum of fed mice (n=16) were
analysed by ELISA. Hypothyroid TRH-R1 ko mice exhibited reduced leptin expression in fat
tissue and leptin serum levels compared to WT controls and euthyroid-rendered mutant mice.
Data are presented as mean ± s.d.: **P<0.005, ***P<0.001.
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3.12A). In agreement with the observed changes in fat mass and leptin mRNA levels,
analysis of serum leptin levels revealed a decrease by 55% in hypothyroid TRH-R1 ko
compared to WT mice and a normalisation in TH-treated mutant mice (Fig. 3.12B).
3.3 Metabolic Consequences of Hypothyroidism
3.3.1 Hypothyroid Mouse Models
To further verify that the pronounced changes in energy metabolism found in hypothy-
roid TRH-R1 ko mice are solely due to the hypothyroidal state of the animals and
not caused by the missing TRH-R1, two additional hypothyroid mouse models were
subjected to metabolic analysis. Pax8 ko mice were included in the study, since these
mouse mutants are born without a functional thyroid gland and consequently do not
show any endogenous TH production. In order to ensure a normal development, the
Pax8 ko mice were substituted with TH for the ﬁrst ﬁve weeks before the TH treat-
ment was terminated. Within the following three weeks, adult Pax8 ko mice became
athyroid as demonstrated by measuring the serum TH concentrations that revealed
complete absence of total T4 and T3 in the serum (Fig. 3.13). As another hypothy-
roid mouse model, WT mice on a C57BL/6 background were treated for 8 weeks with
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Figure 3.13: Serum thyroid hormone concentrations of adult (3-5 months) mice.
After birth, Pax8 ko mice received TH for the ﬁrst ﬁve weeks to ensure normal development
and then TH treatment was discontinued so that the mice were completely athyroid in adult-
hood. The adult Pax8 ko animals did not show detectable serum levels of T4 and T3. WT
mice were rendered hypothyroid by sodiumperchlorate and MMI treatment for 8 weeks and
exhibited reduced total T4 and T3 levels compared to littermates. General note: Mice
are from diﬀerent genetic backgrounds. Pax8 mice exhibit a mixed genetic
background between C57BL/6 and NMRI and WT mice are on a C57BL/6
background. Data are presented as mean ± s.d. of 5 animals per group: ***P<0.001.
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2-mercapto-1-methylimidazole (MMI) and sodium perchlorate via the drinking water
in order to block endogenous TH production. As a consequence of this treatment, the
animals showed a 17.5-fold decrease in total serum T4 and a 5.5-fold decrease in total
T3 compared to untreated littermates (Fig. 3.13).
3.3.2 Food Intake and Body Weight
In agreement with the ﬁndings in hypothyroid TRH-R1 ko mice, athyroid Pax8 ko
and hypothyroid-rendered WT (WT+MMI) mice exhibited a reduction of 15% and
17% in their daily caloric intake, respectively (Fig. 3.14A). The decrease in food
intake was paralleled by a reduction in body weight in both groups: Pax8 ko mice
showed a reduction of 30% and hypothyroid WT mice a reduction of 12% in body
weight compared to the respective euthyroid controls (Fig. 3.14B). Of note, on a
mixed (C57BL/6 x NMRI) genetic background, euthyroid Pax8 WT mice exhibited
a higher food intake and body weight compared to euthyroid WT mice on a pure
C57BL/6 background.
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Figure 3.14: Basal food intake and body weight of adult hypothyroid mice com-
pared to euthyroid controls. The mice were treated as described in the legend of Fig. 3.13.
Food intake (A) is indicated as kcal consumed per day. Body weight (B) was determined
under fed conditions on a regular chow diet. Food intake and body weight were signiﬁcantly
decreased in athyroid Pax8 ko and hypothyroid WT mice compared to euthyroid controls.
Data are presented as mean ± s.d. of >5 animals per group: *P<0.05, ***P<0.001.
3.3.3 Fat Content
Quantiﬁcation of vc and sc fat depots of hypothyroid mice by micro-CT revealed a
marked reduction in fat mass compared to euthyroid controls. The strongest diﬀer-
ences were found in Pax8 ko mice that showed a 80% reduction in vc and a 70%
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reduction in sc fat mass compared to Pax8 WT controls (Fig. 3.15). WT mice that
were rendered hypothyroid exhibited 39% less vc and 37% reduced sc fat mass com-
pared to untreated littermates. Diﬀerences in fat mass between Pax8 WT (mixed
background) and WT (C57BL/6) mice are due to the diﬀerent genetic backgrounds
of these two animal models.
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Figure 3.15: White fat mass of adult hypothyroid mice compared to euthyroid
controls. The mice were treated as described in the legend of Fig. 3.13. The amount of
vc and sc white fat of >5 animals per group was determined by micro-CT and normalised
to total body weight. Athyroid Pax8 ko and hypothyroid WT mice exhibited a reduction in
both vc and sc fat mass compared to euthyroid controls. Data are presented as mean ± s.d.:
**P<0.005, ***P<0.001.
3.3.4 Leptin Production
Leptin production was found to be aﬀected in hypothyroid TRH-R1 ko mice. The
next study was initiated to investigate whether leptin mRNA expression and leptin
serum levels were altered in the above mentioned hypothyroid mouse models as well.
Leptin gene expression in eWAT was found to be decreased by 76% in Pax8 ko animals
and by 48% in MMI-treated WT mice (Fig. 3.16A). In agreement with the decreased
fat mass and the reduction in leptin mRNA expression, these animals also exhibited
lower serum leptin levels with a 5.8-fold reduction in Pax8 ko mice and a 1.5-fold
reduction in MMI-treated WT mice (Fig. 3.16B). The wide range in leptin serum
levels between the WT animals reﬂects again their diﬀerent genetic backgrounds.
TH may inﬂuence leptin expression by acting on its promoter, thereby regulating
leptin production directly. Alternatively, TH may also aﬀect leptin expression in
adipocytes in an indirect manner by e.g., aﬀecting the sympathetic or the parasympa-
thetic output to the adipose tissue. In order to discriminate between these two modes
of action, primary 3T3-L1 adipocytes were cultured and the eﬀect of T3 (50 nM, 6h
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Figure 3.16: Leptin mRNA expression in eWAT and leptin serum levels in hy-
pothyroid mice and euthyroid controls. A) Relative gene expression of leptin in eWAT
was measured by real-time PCR and normalised to HPRT in >5 animals per group. B)
Leptin levels in the serum of fed mice (n>5) were analysed by ELISA. In athyroid Pax8
ko and hypothyroid WT mice, leptin mRNA expression in white fat and leptin serum levels
were signiﬁcantly decreased compared to euthyroid controls. Data are presented as mean ±
s.d.: *P<0.05, **P<0.005.
and 12 h) on leptin expression was evaluated. As shown in Fig. 3.17, treatment of
adipocytes with 50 nM T3 induced an approximately 1.5-fold increase in leptin mRNA
expression already after 6 h and persisted until 12 h. Since T3 stimulates FAS gene
expression in vivo, expression levels were also determined in 3T3-L1 adipocytes. As
expected, FAS mRNA expression was increased approximately 1.5-fold after 6 h and
2-fold after 12 h of T3 treatment. These data indicate that the in vivo TH eﬀects on
leptin production are at least partially due to a direct eﬀect at the cellular level.
   	 	



















		

	




Figure 3.17: Leptin and FAS mRNA expression in 3T3-L1 adipocytes after T3
stimulation. After adipose diﬀerentiation, 3T3-L1 cells were left untreated or were treated
with T3 for 6 h and 12 h. Relative gene expression of leptin and of the T3-regulated gene
FAS (used as a positive control) was measured by real-time PCR and normalised to HPRT in
3 replicates. Following T3 stimulation for 6 h and 12 h, leptin and FAS mRNA expression
was increased compared to untreated cells. Data are presented as mean ± s.d.: *P<0.05.
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3.4 Hypothyroidism and the Central Leptin
Signalling Pathway
3.4.1 Thyroidal State of the Hypothalamus
This study was initiated to evaluate the thyroidal state in the hypothalamus of hy-
pothyroid mice. The expression of DIO2 is one sensitive marker of the brain’s thyroidal
state, since it is negatively regulated by TH both at the transcriptional and posttrans-
lational level [80, 85, 86, 139]. Whereas T3 directly controls DIO2 gene expression,
T4 is supposed to aﬀect DIO2 activity by enhancing ubiquitin-mediated proteasomal
degradation of this enzyme. Moreover, central DIO2 is critically involved in providing
the rodent brain with T3 by intracellular conversion of T4 to T3 [84, 140]. DIO2 is
expressed in glial cells, including astrocytes and tanycytes, the specialised glial cells
at the wall and ﬂoor of the third ventricle of the mediobasal hypothalamus [141]. The
T3 that is generated by DIO2-expressing glial cells is subsequently provided to neigh-
bouring neurons that express TH receptors in order to regulate the transcription of
T3 target genes.
In the present study, the mRNA expression levels of DIO2 were determined in the
hypothalamus. Total RNA was extracted from whole hypothalami and then subjected
to reverse transcription and quantitative real-time PCR analysis. Hypothalamic DIO2
mRNA levels were 1.5-fold upregulated in hypothyroid TRH-R1 ko mice compared to
WT controls and normalised after TH treatment of the mutant mice (Fig. 3.18).
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Figure 3.18: DIO2 mRNA expression in the hypothalamus as measured by quan-
titative real-time PCR. Relative expression levels of DIO2 were determined in 3-7 adult
animals per group and normalised to cyclophilin D. Hypothyroid TRH-R1 ko mice exhibited
increased hypothalamic DIO2 mRNA expression compared to WT controls. TH treatment of
the mutant mice normalised DIO2 expression. Data are mean ± s.d.: **P<0.005.
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Figure 3.19: Hypothalamic T4 and T3 content. The determination of T4 and T3
concentrations was made on pooled hypothalami obtained from 5 adult animals. Hypothyroid
TRH-R1 ko mice exhibited signiﬁcantly decreased hypothalamic T4 and T3 values compared
to WT controls, indicating that the hypothalamus of TRH-R1 ko mice is in a hypothyroid
state. Treatment of the mutant mice increased hypothalamic TH concentrations. Data are
presented as mean of 5 samples ± s.e.m.: *P<0.05, **P<0.005, ***P<0.001.
In order to investigate whether the increase in hypothalamic DIO2 expression in hy-
pothyroid TRH-R1 ko mice results in altered TH levels, hypothalamic T3 and T4
concentrations were determined. For the analysis, hypothalami from ﬁve mice were
pooled. Despite the increased DIO2 expression, hypothalamic T3 and T4 levels were
decreased in TRH-R1 ko mice compared to WT animals (Fig. 3.19). TH treatment of
the mutant mice reversed T4 levels completely, whereas T3 levels showed only a slight,
but signiﬁcant increase compared to the hypothyroid TRH-R1 ko mice. The increase
in hypothalamic DIO2 expression might promote some intracellular conversion of T4
to T3, but this does not contribute to a normalisation of the T3 content. These results
indicate a hypothyroid state in the hypothalamus of TRH-R1 ko mice.
3.4.2 Metabolic Characterisation of TRH-R1/ob dko Mice
As a hypothyroid condition in the hypothalamus may change the central sensing of
peripheral energy signals, the regulation of the leptin signalling pathway in the CNS
of hypothyroid mice was further investigated. In order to evaluate the impact of TH
on leptin signalling, TRH-R1 ko mice (C57BL/6) were crossed with leptin-deﬁcient
ob/ob animals (C57BL/6), thereby generating TRH-R1/ob double knockout (R1/ob
dko) mice. As expected, R1/ob dko mice were hypothyroid due to the lack of TRH-
R1: total T4 and T3 serum levels were both reduced by a factor of approximately
2 compared to WT controls (Fig. 3.20). As controls, R1/ob dko mice at the age
of 3-4 weeks were treated with TH. The determination of TH levels revealed a 1.6-
fold increase in total T4 and a 2-fold increase in T3 levels in TH-treated R1/ob dko
39
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Figure 3.20: Thyroid hormone concentrations in the serum of adult (3-5 months)
mice. R1/ob dko mice showed decreased total T4 and total T3 concentrations compared to
ob/ob and WT control mice. To render hypothyroid R1/ob dko mice euthyroid, animals
were supplied with TH (R1/ob+TH) via the drinking water (4 ng T3 and 60 ng T4 per ml
drinking water) after weaning. Values are indicated as mean ± s.d. of >5 animals per group:
*P<0.05, **P<0.005, ***P<0.001, n.s.; not signiﬁcant.
compared to hypothyroid R1/ob dko mice. Total T4 and T3 levels of ob/ob mice were
within the range of WT mice and can therefore be considered to be euthyroid.
Leptin acts as a peripheral energy signal to regulate body weight in mice. Thus,
leptin administration represses feeding through a central eﬀect in the hypothalamus
[32, 33, 37] and promotes energy expenditure by activating the sympathetic nervous
system [142, 143]. Leptin deﬁciency in ob/ob mice has striking metabolic conse-
quences: compared to WT mice, the daily food intake is stimulated by 30% (Fig.
3.21A) and body weight is increased even by a factor of 2 (Fig. 3.21B). However, the
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Figure 3.21: Basal food intake and body weight of euthyroid and hypothyroid
leptin-deﬁcient mice compared to WT controls. Food intake (A) and body weight (B)
were determined in adult animals (n>5) kept on a regular chow diet. All leptin-deﬁcient ani-
mals exhibited increased food intake and body weight compared to euthyroid, leptin-expressing
WT controls. Data are presented as mean ± s.d.: *P<0.05, **P<0.005, ***P<0.001.
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Figure 3.22: Oxygen consumption and physical activity of obese mice and lean
controls. The measurement was performed for 24 h with a regular 12-h light/12-h dark
cycle. The double-headed arrow indicates the dark phase. The animals (>5 per group) had
free access to food and water. A) Oxygen consumption was measured by indirect calorimetry
and normalised to (body weight)0.67. B) Horizontal movements were assessed by counting
light beam breaks. Compared to the lean WT controls, all leptin-deﬁcient groups of obese
mutant mice exhibited a strong decrease in oxygen consumption and locomotor activity. Data
are mean ± s.e.m. of four time points with an interval of 15 min: §P<0.001.
diﬀerences in food intake and body weight under hypothyroid conditions, as shown in
TRH-R1 ko mice (Fig. 3.4), disappeared in R1/ob dko mice. Food intake and body
weight did not diﬀer in hypothyroid R1/ob dko, euthyroid-rendered R1/ob dko, and
euthyroid ob/ob mice, suggesting that leptin action overrides any inﬂuence of TH on
food intake and body weight.
The eﬀect of leptin deﬁciency on energy expenditure was evaluated by determining oxy-
gen consumption and locomotor activity. As expected, ob/ob mice showed a marked
decrease in oxygen consumption of approximately 23% (Fig. 3.22A, left) which was
paralleled by a substantial reduction in locomotor activity of about 86% (Fig. 3.22B,
left) compared to WT mice. Similar to the food intake and body weight, the diﬀer-
ences in energy expenditure in hypothyroid TRH-R1 ko mice (Fig. 3.5) disappeared
in R1/ob dko mice (Fig. 3.22A and B, right) demonstrating the dominant role of
leptin in the regulation of energy metabolism.
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3.4.3 Hypothalamic Leptin Receptor and SOCS3
Expression
To elucidate whether the central hypothyroidal state of the mice aﬀects leptin sig-
nalling, transcript levels of leptin targets were analysed in the hypothalamus by in
situ hybridisation (ISH) using radioactively labeled riboprobes. In addition, laser-
capture microdissection and quantitative real-time PCR were exploited to quantify
transcript levels speciﬁcally in the arcuate nucleus (ARC). The actions of leptin in
mice are mediated by at least ﬁve leptin-receptor splice variants (Ob-Ra to Ob-Re)
of which Ob-Rb appears to be the functional, signal-transducing isoform responsible
for the hypothalamic actions of leptin [41, 42, 45]. For SOCS3 a potential role as
an inhibitor of the leptin signalling cascade has been described: SOCS3 can mask
phosphotyrosine residues on the leptin receptor and the catalytic region of the Janus
kinase 2 (JAK2) thus preventing downstream signalling [58–60]. Studies were initiated
to determine whether leptin receptor (Ob-R) and SOCS3 are diﬀerentially expressed
under hypothyroid conditions. For ISH, a riboprobe recognising all leptin receptor
isoforms was applied and for real-time PCR, isoform-speciﬁc primers were used.
Initial analysis of hypothalamic Ob-R and SOCS3 mRNA expression by ISH revealed
diﬀerences between hypothyroid mice and euthyroid controls with regard to signal
intensities. As shown in Fig. 3.23, hypothalamic Ob-R expression was markedly in-
creased in hypothyroid TRH-R1 ko mice compared to WT animals and downregulated
Figure 3.23: Hypothalamic Ob-R and SOCS3 mRNA expression in hypothyroid
mice and controls. Basal Ob-R and SOCS3 mRNA expression levels were analysed in
adult mice by radioactive ISH on 20 μm coronal brain sections. Diﬀerences in expression
levels between hypothyroid TRH-R1 ko and athyroid Pax8 ko mice and euthyroid controls
were prominent in the ARC. Whereas Ob-R mRNA expression was markedly increased in
TRH-R1 ko and Pax8 ko mice, SOCS3 mRNA levels were reduced compared to WT controls
and TH-treated TRH-R1 ko mice. Scale bar represents 100 μm.
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to WT levels upon TH treatment of the mutant mice. In contrast, SOCS3 expression
was decreased in hypothyroid mice compared to WT and TH-treated TRH-R1 ko
mice. Despite the known expression pattern of the Ob-R and of SOCS3 within the hy-
pothalamus [13, 61, 144], the diﬀerences in gene expression between hypothyroid and
euthyroid mice were restricted to neurons in the ARC. Surprisingly, the expression
of the Ob-R and of SOCS3 in other hypothalamic regions such as the ventromedial
hypothalamus (VMH) appeared to be unaﬀected by the thyroidal state of the mice.
Intriguingly, athyroid Pax8 ko mice showed the same striking diﬀerences with high Ob-
R and reduced SOCS3 mRNA levels speciﬁcally in the ARC as hypothyroid TRH-R1
ko mice (Fig. 3.23).
The decreased leptin levels found in hypothyroid TRH-R1 ko and athyroid Pax8 ko
mice (Fig. 3.12 and 3.16) may be the primary cause for an increase in leptin recep-
tor expression. As leptin has already been shown to regulate hypothalamic SOCS3
expression [61], it is feasible that leptin also regulates hypothalamic Ob-R expression.
To discriminate between leptin eﬀects and TH-induced changes in hypothalamic Ob-
R expression, animals that diﬀer in the thyroidal state but exhibit the same serum
leptin levels were analysed. For this purpose, TRH-R1 ko mice were crossed with
leptin-deﬁcient ob/ob mice to obtain leptin-deﬁcient and hypothyroid R1/ob dko mice
(section 3.4.2). These mice were then treated with the same amounts of leptin (ip,
2 μg/g bw, twice daily for three days) as leptin-deﬁcient ob/ob mice. As controls,
TH-treated R1/ob dko mice received the same dose of leptin.
Analysis of hypothalamic Ob-R mRNA expression by ISH before leptin treatment
revealed elevated signal intensities in the ARC of hypothyroid R1/ob dko mice com-
pared to euthyroid ob/ob animals which normalised when R1/ob dko animals were
treated with TH (Fig. 3.24A, upper panel). Upon leptin injection, Ob-R expression
decreased in all animal groups, but was still higher in hypothyroid R1/ob dko mice
compared to ob/ob and TH-treated R1/ob dko animals (Fig. 3.24A, lower panel).
These ﬁndings indicate that both TH and leptin play a role in the regulation of Ob-R
expression.
SOCS3 expression was close to the detection limit in the leptin-deﬁcient groups com-
pared to WT animals probably due to the missing leptin stimulus (Fig. 3.24B, upper
panel). After leptin administration, SOCS3 expression was induced in all animals as
expected (Fig. 3.24B, lower panel). Of note, SOCS3 mRNA levels in the ARC of hy-
pothyroid R1/ob dko mice were decreased compared to those in ob/ob and euthyroid
R1/ob dko mice following leptin treatment. Thus, these data indicate that in mice,
in addition to leptin, also TH regulate SOCS3 expression in the ARC.
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Figure 3.24: Hypothalamic Ob-R and SOCS3 mRNA expression in response
to leptin in euthyroid and hypothyroid leptin-deﬁcient mice compared to WT
controls. Changes in Ob-R and SOCS3 expression following administration of recombinant
leptin (ip, 2 μg/g bw, twice daily) for three days. Radioactive ISH was performed on 20 μm
coronal brain sections of adult mice. A) Ob-R mRNA expression in the ARC of hypothyroid
R1/ob dko (R1/ob) mice was markedly increased compared to euthyroid ob/ob mice and
WT controls and normalised after TH treatment of R1/ob dko mice (R1/ob+TH). Leptin
treatment resulted in a downregulation of Ob-R mRNA expression in all animal groups.
B) Leptin treatment resulted in an upregulation of SOCS3 mRNA expression in all animal
groups. After leptin treatment, SOCS3 expression in the ARC of hypothyroid R1/ob dko
mice was decreased compared to euthyroid ob/ob mice and WT controls and normalised
after TH treatment. Scale bars represent 100 μm.
Laser-capture microdissection and quantitative real-time PCR were used in order to
validate the ISH results obtained in the hypothalamic ARC of leptin-treated R1/ob
dko mice. The results revealed a 1.9-fold increase in total Ob-R mRNA expression
and a 2.3-fold downregulation of SOCS3 in hypothyroid R1/ob dko mice compared to
euthyroid ob/ob animals following the leptin treatment (Fig. 3.25). These ﬁndings
are in agreement with the ISH data. Gene expression analysis of the diﬀerent Ob-R
isoforms showed an increase in the expression of the short isoforms Ob-Ra (3.4-fold)
and Ob-Rc (1.6-fold) in ARC neurons of R1/ob dko compared to ob/ob mice, whereas
the main signalling isoform Ob-Rb was not signiﬁcantly changed.
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Figure 3.25: Gene expression of Ob-R and SOCS3 in the ARC of ob/ob and
R1/ob dko mice after leptin treatment as measured by real-time PCR. Relative
expression levels of total Ob-R mRNA, its isoforms Ob-Ra, Ob-Rb, and Ob-Rc as well as
of SOCS3 were determined in >5 adult animals per group and normalised to cyclophilin
D. Animals were treated with recombinant leptin (ip, 2 μg/g bw, twice daily) for three days.
Tissue of the ARC was dissected by laser-capture microdissection. Values from hypothy-
roid R1/ob dko mice are expressed in relation to those of euthyroid ob/ob controls. After
leptin treatment, gene expression of total Ob-R and of the short forms, Ob-Ra and Ob-Rc,
was increased in hypothyroid R1/ob dko mice compared to euthyroid ob/ob mice, whereas
SOCS3 mRNA expression was decreased. Data are presented as mean ± s.e.m.: *P<0.05,
**P<0.005, ***P<0.001.
3.4.4 Phosphorylation of Stat3 in Response to Leptin
In order to test the response of hypothyroid mice to leptin, the phosphorylation of
the signal transducer and activator of transcription 3 (Stat3) in response to leptin
was evaluated in hypothyroid R1/ob dko and euthyroid ob/ob mice by immunohisto-
chemistry (IHC). Detection of nuclear phospho-Stat3-immunoreactivity (IR) after a
single leptin injection has become a well accepted method for the functional mapping
of central leptin actions [145]. Again, TH-treated R1/ob dko mice were included in
the study as euthyroid controls. The mice were given a single injection of recombi-
nant mouse leptin (ip, 2 μg/g bw) and were sacriﬁced 45 min later. In unstimulated
leptin-deﬁcient animals, phospho-Stat3-IR was not detectable, whereas in untreated
WT mice phospho-Stat3-IR was restricted to a few neuronal nuclei located in the ARC
(Fig. 3.26, upper panel). In agreement with the literature [146], peripheral administra-
tion of leptin induced phospho-Stat3-IR in the ARC of all animal groups. Remarkably,
in the ARC of hypothyroid R1/ob dko mice less phospho-Stat3 immunopositive neu-
rons were found in response to leptin administration compared to ob/ob mice (Fig.
3.26, lower panel). However, when the R1/ob dko mice were treated with TH, this
diﬀerence disappeared. The TH-treated R1/ob dko mice exhibited a similar increase
in phospho-Stat3-IR in response to leptin administration as the WT mice.
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Figure 3.26: Immunohistochemical analysis of phosphorylated Stat3 in hypotha-
lami of adult mice before and after leptin treatment. Coronal brain sections (20 μm)
were obtained and subjected to IHC using anti-pY(705)-STAT3 antiserum. Upper panel: in
unstimulated WT mice, phospho-Stat3-IR was only detectable in a few nuclei of neurons
located in the ARC, whereas no speciﬁc signals were found in untreated leptin-deﬁcient mice.
Lower panel: mice were given a single ip injection of recombinant leptin (2 μg/g bw) and
sacriﬁced 45 min later. Upregulation of phospho-Stat3 was less pronounced in hypothyroid
R1/ob dko mice whereas TH-treated R1/ob dko mice showed a similar response as ob/ob
mice. Scale bar represents 100 μm.
The results obtained in hypothyroid R1/ob dko mice suggest that ARC neurons of hy-
pothyroid mice are less responsive to peripheral leptin than those of euthyroid mice. In
order to verify this hypothesis, ob/ob mice were made hypothyroid by treatment with
the goitrogenic agents sodiumperchlorate and MMI and the upregulation of Stat3 in
response to leptin treatment was analysed again. After 8 weeks of goitrogen treatment,
serum T4 concentrations were below detection limit and T3 levels were decreased by
a factor of 4.2 compared to ob/ob controls (Fig. 3.27A). Upon a single injection of
recombinant leptin (ip, 2 μg/g bw), the hypothyroid and euthyroid ob/ob mice were
sacriﬁced 45 min later and phosphorylation of Stat3 was monitored by IHC. Nuclear
phospho-Stat3-IR was found to be decreased in ARC neurons of hypothyroid-rendered
ob/ob mice (ob/ob+MMI) compared to euthyroid controls after leptin treatment (Fig.
3.27B). These ﬁndings are in line with the results obtained in hypothyroid R1/ob dko
mice and thus conﬁrm a reduced central response to peripheral leptin in hypothyroid
mice.
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Figure 3.27: Eﬀect of treatment of ob/ob mice with the goitrogenic agent MMI
on serum thyroid hormone levels and on the phosphorylation of Stat3 in the
ARC after leptin administration. A) To render ob/ob mice hypothyroid, they were
treated with sodiumperchlorate and MMI for 8 weeks starting at the age of 2 months. Serum
levels of T4 were below the detection limit following the MMI treatment, whereas total T3
levels were signiﬁcantly decreased compared to untreated ob/ob mice. Values are indicated as
mean ± s.d. of 5 animals per group: ***P<0.001. B) Coronal brain sections (20 μm) were
subjected to IHC using an anti-pY(705)-STAT3 antiserum. Upper panel: in unstimulated
euthyroid and hypothyroid ob/ob mice, phospho-Stat3-IR was not detectable. Lower panel:
mice were given a single ip injection of recombinant leptin (2 μg/g bw) and sacriﬁced 45
min later. Upregulation of phospho-Stat3 was less pronounced in hypothyroid ob/ob mice
compared to euthyroid controls. Scale bar represents 100 μm.
3.4.5 Metabolic Response to Leptin Treatment
Does a reduced leptin response in hypothalamic neurons of hypothyroid mice aﬀect
leptin-induced alterations in body weight and food intake? In order to address this
question, hypothyroid leptin-deﬁcient animals and controls were injected for three
days twice daily with recombinant leptin (ip, 2 μg/g bw) and changes in body weight
and food intake were monitored. For calculation, values prior to the treatment were
set to 100%.
All mice showed a response to leptin administration with a decrease in food intake and
body weight. However, diﬀerences in the leptin response between hypothyroid and
euthyroid mice could be clearly detected. While hypothyroid R1/ob dko mice had a
maximal decrease in food intake of 54% on the second day of treatment, euthyroid
ob/ob mice showed an even stronger suppression of 87% on the ﬁrst day of leptin
withdrawal (W1) (Fig. 3.28A, left). During the time period of leptin withdrawal,
hypothyroid R1/ob dko mice consumed appoximately 30% more food compared to
euthyroid ob/ob mice. These changes in food intake were paralleled by a decrease in
body weight, which was approximately 5% less in R1/ob dko compared to ob/ob mice
(Fig. 3.28A, right). Both groups responded to the cessation of leptin treatment with
an increase in body weight. However, due to the stronger leptin eﬀect in ob/ob mice,
normalisation was delayed in ob/ob mice compared to R1/ob dko animals. Similar
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Figure 3.28: Alterations in food intake and body weight in response to leptin
treatment and rebound eﬀects after leptin withdrawal. Adult mice were ip injected
with recombinant mouse leptin (2 μg/g bw, twice daily) for three days. Changes in food
intake and body weight were determined for three days of treatment and ﬁve days after
withdrawal (W1-5). Food intake is expressed as a percentage of the baseline intake, which
was calculated as the average daily food intake of the last four days before treatment. Body
weight is expressed as a percentage of the body weight determined on the day before the
leptin treatment. A) Changes in food intake and body weight of hypothyroid R1/ob dko mice
compared to euthyroid ob/ob mice. B) Changes in food intake and body weight of hypothyroid
ob/ob mice compared to controls. Hypothyroid R1/ob dko and hypothyroid-rendered ob/ob
mice showed a diminished suppression of food intake and reduced loss of body weight in
response to leptin compared to euthyroid ob/ob mice. Data are mean ± s.e.m. for groups of
5-8 mice: *P<0.05, #P<0.005, §P<0.001.
changes in food intake and body weight were observed when hypothyroid ob/ob mice
and euthyroid controls were treated with leptin (Fig. 3.28B). In line with the previous
results, the maximal suppression of food intake was less in hypothyroid ob/ob mice.
Compared to euthyroid controls that exhibited a suppression of food intake of 90%,
the hypothyroid ob/ob mice had a maximal decrease in food intake of 50% (Fig. 3.28B,
left). The diﬀerential response to peripheral leptin was also reﬂected by the loss of
body weight: hypothyroid ob/ob mice lost at most 6.6% of their initial weight whereas
euthyroid controls had a maximal loss of 11.3% (Fig. 3.28B, right).
48
3.4 Hypothyroidism and the Central Leptin Signalling Pathway
3.4.6 Hypothalamic AgRP and POMC Expression
The reduced metabolic responses to leptin treatment in hypothyroid mice suggest
that the central integration of the leptin signal and therefore central leptin signalling
may be impaired under hypothyroid conditions. To unravel the underlying molecular
mechanisms that could promote diminished leptin signalling, transcript levels of two
target genes of Stat3 were analysed. It has been demonstrated that the transcription
factor Stat3 can decrease the expression of agouti-related peptide (AgRP) and can
induce the expression of proopiomelanocortin (POMC), two neuropeptides synthesised
in ARC neurons [37, 147]. In this study, the expression of AgRP and POMC mRNA
was evaluated by ISH using digoxigenin-labeled riboprobes. In parallel experiments,
laser-capture microdissection was performed to assess transcript levels speciﬁcally in
the ARC by quantitative real-time PCR.
The ISH analysis revealed an increase in AgRP mRNA expression in ARC neurons of
hypothyroid TRH-R1 ko compared to WT controls (Fig. 3.29, upper panel). However,
when TRH-R1 ko mice were treated with TH, this diﬀerence disappeared. As expected,
athyroid Pax8 ko mice exhibited a similar upregulation of AgRP expression as the
hypothyroid TRH-R1 ko mice. In contrast, POMC mRNA levels were repressed in
TRH-R1 ko and Pax8 ko mice compared to WT animals and normalised after TH
treatment of TRH-R1 ko mice (Fig. 3.29, lower panel).
Figure 3.29: Hypothalamic AgRP and POMC mRNA expression in hypothyroid
mice and controls. Basal AgRP and POMC mRNA expression was analysed in adult
mice by DIG-labeled ISH on 20 μm coronal brain sections. Diﬀerences in mRNA expression
between hypothyroid TRH-R1 ko and athyroid Pax8 ko mice and euthyroid controls were
prominent in the ARC. Whereas AgRP expression was markedly increased in TRH-R1 ko
and Pax8 ko mice, POMC mRNA levels were reduced compared to WT controls and TRH-R1
ko mice after TH treatment. Scale bar represents 100 μm.
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Figure 3.30: Hypothalamic AgRP and POMC mRNA expression in response
to leptin in euthyroid and hypothyroid leptin-deﬁcient mice compared to WT
controls. Changes in AgRP and POMC expression was analysed following administration
of recombinant leptin (ip, 2 μg/g bw, twice daily) for three days. DIG-labeled ISH was
performed on 20 μm coronal brain sections of adult mice. A) AgRP mRNA expression in
the ARC of leptin-deﬁcient mice was markedly increased compared to WT controls. Leptin
treatment resulted in a downregulation of AgRP expression. B) POMC mRNA expression in
the ARC of leptin-deﬁcient mice was markedly decreased compared to WT controls. Leptin
treatment resulted in an upregulation of POMC expression. Scale bars represent 100 μm.
The diﬀerences in AgRP and POMC expression between hypothyroid (TRH-R1 ko,
Pax8 ko) and euthyroid (WT, euthyroid TRH-R1 ko) mice, however, might be primar-
ily mediated by the dissimilar leptin serum levels of the mice. To test this hypothesis,
AgRP and POMC mRNA expression in leptin-deﬁcient hypothyroid R1/ob dko and
euthyroid ob/ob mice that were treated with the same dose of recombinant leptin (2
μg/g bw, twice daily for three days) was analysed. As controls, TH-treated R1/ob dko
mice were included in the study. As expected, leptin treatment markedly repressed
AgRP expression in leptin-deﬁcient mice (ob/ob, R1/ob, and R1/ob+TH) and had
only little eﬀects in WT mice (Fig. 3.30A). In contrast, POMC expression was in-
duced by leptin stimulation in all animal groups (Fig. 3.30B). However, no diﬀerences
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Figure 3.31: Gene expression of AgRP and POMC in the ARC of ob/ob and
R1/ob dko mice before and after leptin treatment as determined by real-time
PCR. Relative expression levels of AgRP and POMC were determined in >5 adult animals
per group and normalised to cyclophilin D. Animals were treated with recombinant leptin (ip,
2 μg/g bw, twice daily) for three days. Tissue of the ARC was dissected by laser-capture
microdissection. Values are expressed in relation to those of euthyroid ob/ob controls. Upon
leptin treatment, AgRP mRNA expression was downregulated, whereas POMC expression
was induced, however, each to a similar extent in hypothyroid R1/ob dko and euthyroid
ob/ob mice. Data are mean ± s.e.m.: *P<0.05, ***P<0.001.
in AgRP and POMC expression were found in ARC neurons of hypothyroid R1/ob
dko compared to euthyroid ob/ob mice following leptin treatment.
Gene expression studies in the ARC showed an approximately 5-fold downregulation
of AgRP expression in hypothyroid R1/ob dko and euthyroid ob/ob mice in response
to leptin treatment (Fig. 3.31). However, there were no signiﬁcant diﬀerences in gene
expression between the genotypes before and after the leptin treatment. In contrast,
POMC expression was increased by a factor of 2.3 and 3.7 in ob/ob and R1/ob dko
mice, respectively, following leptin stimulation. Again, no signiﬁcant diﬀerences in
POMC expression between genotypes before and after leptin treatment were observed.
The results obtained by LCM and real-time PCR were in agreement with the ﬁndings
of the ISH experiments.
3.4.7 Hypothalamic PTPN1 Expression
Another possibility to explain the alterations in hypothalamic leptin signalling in
hypothyroid mice might be changes in the gene expression of the protein tyrosine
phosphatase type 1 (PTPN1). This protein interferes with the leptin signalling path-
way and might be involved in the development of central leptin resistance. Expression
of PTPN1 is found in the hypothalamus, where it is highly enriched in the ARC. In-
creased hypothalamic PTPN1 levels were found during a high-fat diet induced leptin
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Figure 3.32: Hypothalamic PTPN1 mRNA expression in response to leptin in
euthyroid and hypothyroid leptin-deﬁcient mice compared to WT controls. A)
PTPN1 expression in unstimulated mice and following administration of recombinant lep-
tin (ip, 2 μg/g bw, twice daily) for three days revealed no diﬀerences between genotypes.
Radioactive ISH was performed on 20 μm coronal brain sections of adult mice. Scale bar
represents 100 μm. B) Relative mRNA expression levels of PTPN1 were determined in >5
adult animals per group and normalised to cyclophilin D. Animals were treated with recom-
binant leptin (ip, 2 μg/g bw, twice daily) for three days. Tissue of the ARC was dissected by
laser-capture microdissection. Values are expressed in relation to those of euthyroid ob/ob
controls and revealed no signiﬁcant diﬀerences. Data are mean ± s.e.m.
resistance in rodents [65]. PTPN1 has been shown to negatively regulate leptin sig-
nalling by dephosphorylating the Janus kinase 2, thereby inhibiting the leptin-induced
JAK2/STAT3 pathway [62–64].
PTPN1 transcript levels were initially assessed by radioactive ISH (Fig. 3.32A). How-
ever, no diﬀerences were found between hypothyroid R1/ob dko and euthyroid ob/ob
mice, neither with regard to signal intensities nor to the cellular distribution pattern.
Also, compared to TH-treated R1/ob dko mice and WT animals, hypothyroid R1/ob
dko mice exhibited no diﬀerences in PTPN1 expression. Moreover, leptin treatment
of the mice had no inﬂuence on PTPN1 mRNA levels either. The results of the ISH
were conﬁrmed by quantitative real-time PCR analysis (Fig. 3.32B). Therefore, tissue
speciﬁcally from the ARC was dissected by laser-capture microdissection. Following
leptin treatment, PTPN1 gene expression was not diﬀerent in hypothyroid R1/ob dko
compared to euthyroid ob/ob mice.
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Discussion
4.1 Thyroid Hormones are Essential Regulators of
Energy Metabolism
Thyroid hormones (TH) play an essential role not only during development, but also
in adult life. In adults, TH regulate many metabolic processes such as the metabolism
of lipids, carbohydrates, and proteins. TH can inﬂuence the metabolic activity of a
particular tissue in a direct manner by activating tissue-speciﬁc TH receptors or in-
directly, by modulating CNS circuits that in turn regulate metabolic processes via
the endocrine and the autonomic nervous system. Within the CNS, a major site
important in the regulation of energy metabolism is the hypothalamus. Peripheral
metabolic signals that convey information about the energy state of the body con-
verge on this site, thereby modulating neuronal activity. Subsequently, changes in the
hypothalamic-pituitary-endocrine axes and in the autonomic nervous system culmi-
nate in alterations of food intake and energy expenditure. The hypothalamus matches
with great precision energy intake and expenditure to maintain constant body weight
and is thus a pivotal site of energy homeostasis. Based on several genetically and
biologically modiﬁed rodent models, a key role for central T3 in the stimulation of ap-
petite and energy expenditure has been delineated [148]. The importance of TH in the
regulation of appetite and body weight is demonstrated by the clinical consequences
in patients with thyroid dysfunctions. Hyperthyroidism, which is characterised by
an excessive production of TH, causes a hypermetabolic state with increased energy
expenditure, reduced body weight, and marked hyperphagia [94, 96]. Conversely, hy-
pothyroidism classically leads to reduced energy expenditure and weight gain [99].
Understanding how peripheral and central signalling pathways that aﬀect the en-
docrine and metabolic axes are regulated by TH will provide new insights into thyroid
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physiology. In light of the increasing worldwide incidence of obesity, this knowledge
may help us to identify new potential therapeutic strategies.
4.2 The TRH-R1 ko Mouse Model
In this study, the TRH-R1 ko mouse was used as a mouse model of hypothyroidism.
Due to the absence of the TRH-R1 on pituitary thyrotrophs, the mice exhibit central
hypothyroidism which is characterised by an insuﬃcient TSH secretion and conse-
quently by reduced TH levels. Indeed, in the TRH-R1 ko mice analysed in this study
a reduction of serum T3 and T4 levels by approximately 50% was detected compared
to their wild type littermates. As a consequence of the low serum TH levels, an
increase in hypothalamic TRH mRNA expression was found as demonstrated by ra-
dioactive in situ hybridisation (Fig. 3.3). Of note, studies in mice have demonstrated
that only hypophysiotropic TRH neurons in the paraventricular nucleus are regulated
by TH, whereas non-hypophysiotropic TRH neurons are not aﬀected [73]. This would
indicate that the upregulation of TRH expression in the paraventricular nucleus of
hypothyroid TRH-R1 ko mice takes place in hypophysiotropic TRH neurons. In ad-
dition to the regulation of the HPT axis by hypothalamic TRH, extra-hypothalamic
TRH was suggested to act as a neuromodulator or neurotransmitter, thereby exerting
a number of physiologic functions [149]. These central TRH eﬀects include the regu-
lation of arousal, locomotor activity as well as behavioural and metabolic alterations.
In addition to TRH-R1, TRH can bind to TRH-R2 isoform which is present in mice
and rats, but not in humans [150]. In the rodent CNS, both receptors have distinct
expression patterns as has been demonstrated by in situ hybridisation [74, 150]. TRH-
R1 mRNA is highly expressed in the neuroendocrine brain regions, the autonomic
nervous system, and the visceral brainstem regions. In contrast, TRH-R2 mRNA is
predominantly expressed in brain areas that are important for the transmission of
somatosensory signals and higher CNS functions. In order to exclude any eﬀects me-
diated by the increased hypothalamic TRH, the TRH-R1 ko mice were treated with
TH via the drinking water from the time of weaning. The data demonstrated that
the treatment with TH not only normalised serum TH levels, but also hypothalamic
TRH expression (Fig. 3.3).
TH-treated TRH-R1 ko mice were also included for another important reason. Given
its presence in the CNS, the absence of TRH-R1 in the brain may also directly aﬀect
the activity of neurons involved in the regulation of energy metabolism. However,
due to the lack of a TRH-R1-speciﬁc antibody, TRH-R1-expressing neurons and their
projections are poorly deﬁned. In order to localise TRH-R1-expressing cells in hy-
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pothalamic nuclei, ISH studies were performed. As a second approach, transgenic
mice were analysed that express EGFP under the control of the TRH-R1 promoter.
With both approaches TRH-R1-expressing cell bodies as well as EGFP-positive axons
could be detected in the lateral hypothalamus, the dorsomedial hypothalamic nucleus,
and the anterior hypothalamus (Fig. 3.2). In comparison, neurons of the arcuate
nucleus and the paraventricular hypothalamic nucleus do not express TRH-R1, but
are targeted by TRH-R1-positive ﬁbers. However, since TH-treated TRH-R1 ko mice
did not show any signiﬁcant metabolic diﬀerences compared to wild type animals, the
absence of TRH-R1 alone does not appear to have a detectable impact on the central
sensing of energy signals. Finally, the alterations observed in TRH-R1 ko mice were
also found in athyroid Pax8 ko or wild type animals that were rendered hypothyroid
by MMI treatment. Overall, the results obtained within this thesis point to an im-
portant role of TH in the regulation of energy metabolism, but do not provide any
evidence for an involvement of TRH-R1.
4.3 Food Intake of TRH-R1 ko Mice
In the regulation of appetite the HPT axis is critically involved as thyroid dysfunction
has been shown to cause clinically signiﬁcant consequences on food intake and body
weight [94, 96]. Traditionally, it has been assumed that the increase in food intake
in hyperthyroidism is a compensatory mechanism in order to replenish energy stores.
Thus, TH have been suggested to regulate indirectly food intake by aﬀecting energy
expenditure. However, recent evidence indicates that the HPT axis may play a direct
role in the hypothalamic regulation of appetite as well. Along this line, the increased
TH levels in hyperthyroidism may act directly on central circuits regulating appetite
thus causing hyperphagia. Indeed, studies in rodent models have demonstrated that
peripheral and central hypothalamic administration of T3 increases food intake and
suggested that T3 directly stimulates food intake at the level of the hypothalamus
[151].
In order to investigate whether food intake is also aﬀected under hypothyroid con-
ditions, the daily caloric intake was analysed in hypothyroid TRH-R1 ko mice on a
normal chow diet. The hypothyroid mice exhibited a signiﬁcant reduction in food
intake compared to wild type littermates (Fig. 3.4). The reduction in food intake
was normalised in TRH-R1 ko mice that were treated with TH indicating that the
eﬀect on food intake is a consequence of the altered TH status and not of the missing
TRH-R1. That hypothyroidism in mice is indeed associated with a decrease in food
intake could be further shown in two additional animal models of hypothyroidism.
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Both, athyroid Pax8 ko mice as well as WT mice that were rendered hypothyroid by
MMI treatment showed a decrease in daily caloric intake (Fig. 3.14). In view of the
above mentioned orexigenic eﬀects of TH, this is a rather expected ﬁnding. It has
been demonstrated that high circulating TH levels stimulate food intake in rodents
and humans. Conversely, one would expect a reduction in food intake when the cir-
culating TH levels decline.
Several mechanisms have been postulated to explain how TH might stimulate ap-
petite. Studies in rats by S. Ishii et al. demonstrated an eﬀect of TH on neuronal
populations in the arcuate nucleus of the hypothalamus [126]. One subpopulation ex-
presses the proopiomelanocortin (POMC) gene which codes for the anorectic (appetite-
suppressing) neuropeptide α-melanocyte stimulating hormone (α-MSH). The other
expresses the orexigenic (appetite-stimulating) factors neuropeptide Y (NPY) and
agouti-related peptide (AgRP). It has been reported that peripheral administration
of thyrotoxic doses of T3 caused an increase in hypothalamic NPY and a decrease
in POMC mRNA levels [126]. Moreover, the intracerebroventricular administration
of a NPY/Y1 receptor antagonist blunted the T3-induced hyperphagia, suggesting
that T3 may increase appetite via NPY. To delineate a possible cause for the altered
food intake in hypothyroid mice, the mRNA expression of hypothalamic POMC and
AgRP was analysed by ISH in TRH-R1 ko and Pax8 ko mice. The analysis of the
hypothalamic neuropeptide expression levels revealed reduced POMC and increased
AgRP mRNA expression levels in the hypothyroid mouse models compared to euthy-
roid controls (Fig. 3.29). Again, TH treatment of the TRH-R1 ko mice normalised
gene expression of POMC and AgRP. However, these changes in neuropeptide expres-
sion do not explain the decreased food intake of the hypothyroid mice. Based on the
increased expression of the orexigenic factor AgRP and the decreased levels of the
anorexigenic neuropeptide POMC, one would rather expect an increase in food intake
in the hypothyroid mice. Until now, the central factors contributing to the reduced
food intake of hypothyroid TRH-R1 ko mice remain still unknown.
4.4 Body Weight of TRH-R1 ko Mice
In the present study, the body weight of hypothyroid mice was determined on a
regular chow diet. In TRH-R1 ko mice, a signiﬁcant reduction in body weight was
found compared to euthyroid wild type mice (Fig. 3.4). TH treatment of the mutant
mice improved, but did not reverse completely the phenotype. The data obtained in
TRH-R1 ko mice are in agreement with observations in humans lacking a functional
TRH-R1 [152, 153]. Moreover, genome-wide association studies identiﬁed TRH-R1
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as an important gene for lean body mass (LBM) [154]. Two single-nucleotide poly-
morphisms within the TRH-R1 gene were reported to be associated with lower LBM.
The authors speculated that the lower LBM is caused by an impaired development of
skeletal muscle. In fact, central hypothyroidism has been shown to cause an impaired
expression of myosin heavy chain isoforms and diminished muscle cross-sectional ar-
eas [155, 156]. However, whether muscle development is impaired in hypothyroid
TRH-R1 ko mice is a valid question to be addressed in future studies. The signiﬁ-
cant reduction in body weight found in two other hypothyroid mouse models in this
study, the athyroid Pax8 ko mice and hypothyroid wild type animals, conﬁrmed the
results obtained in hypothyroid TRH-R1 ko mice (Fig. 3.14). The present data thus
reveal that hypothyroidism is rather associated with loosing than with gaining body
weight.
Thyroid Hormones and Body Weight
The crucial role of the HPT axis in the regulation of body weight has been clearly
demonstrated in pathological alterations of the thyroidal state. It is generally accepted
that overt hyperthyroidism results in weight loss due to the thermogenic eﬀects of TH
[157]. Recent studies have demonstrated, however, that weight gain is not a common
characteristic of patients diagnosed with hypothyroidism [97, 157]. Indeed, treatment
of hypothyroid children and adults with TH caused minimal if any weight loss, sug-
gesting that negligible weight gain occurred before the treatment [97, 158]. Moreover,
the expected decrease in metabolic rate could not be found in hypothyroid rodent
models, suggesting that hyperthyroidism and hypothyroidism are not the mirror im-
age of each other [95, 96, 159]. Therefore, the long-lasting assumption that a decrease
in metabolic rate contributes to weight gain in hypothyroidism is refuted. The impres-
sion of increased body weight in hypothyroidism largely comes from the mid 1900s
when patients with severe and long-standing hypothyroidism often developed myx-
oedema with water retention [160].
Actually, studies of hypothyroid rodent models have reported a reduction in body
weight and identiﬁed the brown adipose tissue (BAT) as an eﬀective site that con-
tributes to an increase in energy metabolism. The BAT is a key site of adaptive
thermogenesis that in response to cold exposure increases heat production. This
unique tissue is rich in mitochondria and is highly innervated by catecholaminergic
nerve ﬁbers. Upon cold-induced norepinephrine release, the BAT responds with an
increased expression and activation of the inner mitochondrial membrane protein, un-
coupling protein 1 (UCP1). This unique protein uncouples respiration from ATP
synthesis, thereby producing heat instead of ATP. Studies by C. B. Ueta et al. im-
pressively demonstrated that hypothyroid mice were metabolically sensitive to envi-
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ronmental temperature [159]. Only at room temperature, hypothyroid mice exhibited
reduced body weight and were protected against diet-induced obesity whereas at ther-
moneutrality (~30◦C), hypothyroid mice became as obese as euthyroid controls when
placed on a high-fat diet. An adaptive response in BAT sympathetic activity at room
temperature, which is turned oﬀ at thermoneutrality, has been suggested. In line with
these data are the ﬁndings of M. Sjögren et al. [161]. In this study, mice that were
heterozygous for a dominant-negative mutant TRα1 were analysed. This mutation
caused a 10-fold reduction in the aﬃnity of TRα1 to T3. The animals showed an hy-
permetabolic phenotype with strongly reduced fat depots, hyperphagia and resistance
to diet-induced obesity accompanied by an increase in glucose and fat metabolism in
liver and adipose tissue. Acclimatisation of the mutant mice to 30◦C normalised this
phenotype and caused a rapid weight gain compared to wild type mice. Again, an
activation of the BAT in response to environmental temperature has been shown to
cause the lean phenotype of the mutant mice.
Thyroid Hormones and Brown Adipose Tissue
Adaptive thermogenesis in BAT is an important metabolic process that is regulated by
TH. It is especially relevant in small mammals and infants to increase energy expen-
diture in response to cold environments. The critical role of TH in the regulation of
cold-induced thermogenesis is clearly demonstrated in thyroidectomised rats. These
athyroid rats do not survive in a cold environment due to an impaired upregulation
of the metabolic rate by BAT [114]. TH exert their eﬀects on BAT thermogenesis
either directly via TH receptors that are expressed in brown adipocytes or indirectly
by aﬀecting central TRH neurons that are able to modulate the sympathetic outﬂow
to the BAT.
Within the BAT, two major functions for TH have been described, the close synergism
with the sympathetic nervous system [106–109] and the transcriptional activation of
UCP1 [111, 112]. TH amplify the adrenergic signal transduction in the BAT and this
augmentation of the adrenergic responsiveness has been shown to be dependent on
the TH receptor isoform, TRα [107]. In contrast, the stimulation of UCP1 expression
has been demonstrated to be mediated by the TRβ isoform [111]. In BAT, T3 is
produced locally from T4 by the action of type 2 deiodinase (DIO2). During cold
exposure, DIO2 activity increases which is accompanied by an accelerated conversion
of T4 to T3 [110]. This raise in local T3 concentration allows the BAT to produce
heat in a sustainable manner. The importance of T3 generated by DIO2 in this tissue
has been underlined by the phenotype of DIO2 knockout mice [162]. In these mice,
the disruption of DIO2 resulted in a BAT-speciﬁc hypothyroidism in an otherwise
euthyroid animal. DIO2 knockout mice exhibited insuﬃcient BAT thermogenesis in
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response to cold due to the missing adaptive increase in T4 to T3 conversion. As a
result, the DIO2-deﬁcient mice could survive the cold only by compensatory shivering,
a less eﬃcient thermogenic pathway [113].
The paraventricular nucleus of the hypothalamus (PVN) plays another important role
in the regulation of BAT thermogenesis. Besides the hypophysiotropic TRH neurons
that regulate the HPT axis, the PVN contains non-hypophysiotropic TRH neurons
that do not serve a direct hypophysiotropic function, but rather play a diﬀerent role.
Among other functions, they might be involved in the regulation of the autonomic ner-
vous system to induce thermoregulation. Indeed, studies in Siberian hamsters using
pseudorabies virus as a transneuronal viral tract tracer identiﬁed the hypothalamic
PVN neurons as one particular origin of the sympathetic nervous system outﬂow to
the BAT [163]. Moreover, pre-autonomic PVN neurons were shown to project directly
onto the sympathetic pre-ganglionic cell column of the spinal cord, thereby inﬂuencing
sympathetic activity [164, 165]. Which TRH receptor mediates the autonomic action
of TRH is currently unknown. Based on its localisation, however, a contribution of
TRH-R1 is very likely. Thus, an examination of the BAT in both hypothyroid as
well as euthyroid TRH-R1 ko mice appeared to be an appropriate approach to dissect
TRH versus TH actions in the BAT.
4.5 BAT Thermogenesis of TRH-R1 ko Mice
The metabolic state of the BAT in hypothyroid TRH-R1 ko mice as well as euthyroid
controls was analysed in the following manner. Tissue sections of the BAT were mor-
phologically characterised with regard to the stored fat depots as the amount of lipids
is indicative for the thermogenic capacity of this tissue. Expression levels of genes
involved in BAT thermogenesis were determined as well as tissue T3 concentrations.
The histological analysis of the BAT revealed a marked reduction in the amount of
lipid droplets in hypothyroid TRH-R1 ko mice (Fig. 3.6). Intriguingly, mutant mice
that were treated with TH after weaning time exhibited an increased lipid content
that was similar to that found in the wild type mice. The results suggest that the
morphology of the BAT was rather determined by the thyroidal state of the animals
than by alterations in TRH signalling as a consequence of a missing TRH-R1. More-
over, hypothyroid TRH-R1 ko mice showed increased DIO2 expression in the BAT
accompanied by elevated tissue T3 levels compared to euthyroid mice (Fig. 3.7 and
3.8). The BAT morphology as well as the increased DIO2 expression indicate that
the BAT of these hypothyroid mice is in a recruited state.
Several mechanisms may contribute to the upregulation of DIO2 expression in the
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BAT. Studies in rats have shown that sympathetic stimulation induced the activity of
DIO2 in BAT and increased T3 tissue levels resulted from this activation [110]. More-
over, TRα1 mutant mice were reported to show an increase in basal sympathetic
tone [161]. Thus, a similar scenario could be envisaged for the hypothyroid TRH-R1
mutant mouse. Moreover, DIO2 is also a direct target of TH action both at the
transcriptional and posttranslational level. Whereas T3 negatively regulates DIO2
mRNA expression levels, T4 controls enzyme activity by ubiquitination [85, 86]. Con-
sequently, decreased circulating T4 levels as found in hypothyroid TRH-R1 ko mice
are translated into an increased stability of the DIO2 protein. As a third possibility,
TSH was also suggested to regulate DIO2 expression since TSH receptor expression
has been detected in rat brown adipose tissue [166].
In line with the morphological observations, a detailed gene expression analysis re-
vealed an upregulation of the thermogenic markers peroxisome proliferator-activated
receptor gamma (PPAR-g) and PPAR-g coactivator-1 alpha (PGC-1a) together with
elevated UCP1 transcript levels in the BAT of hypothyroid TRH-R1 ko mice (Fig.
3.7). These changes in gene expression again could be normalised by TH treatment
of the TRH-R1 ko mice. Of note, PPAR response element sites were identiﬁed in
the distal UCP1 promoter that together with the transcriptional coactivator PGC-1a
accelerate the norepinephrine-induced UCP1 gene expression [100]. It is likely that
the expression of PGC-1a and PPAR-g in hypothyroid TRH-R1 ko mice is induced
by an increase in sympathetic BAT stimulation. Moreover, locally produced T3 may
directly regulate UCP1 since thyroid hormone responsive elements were found in the
UCP1 promoter as well [100]. Thus, local T3 and increased sympathetic tone may
act in concert to trigger BAT thermogenesis in hypothyroid animals.
4.6 Oxygen Consumption of TRH-R1 ko Mice
Based on the increased UCP1 expression in the BAT of hypothyroid TRH-R1 ko mice,
thermogenesis seems to be stimulated. In order to investigate the BAT thermogenic
capacity, changes in oxygen consumption were determined by indirect calorimetry. In
line with the upregulation of UCP1, an increase in oxygen consumption was found
only in the hypothyroid TRH-R1 ko mice whereas euthyroid TRH-R1 ko mice did not
show any signiﬁcant diﬀerences compared to wild type animals (Fig. 3.5). This in-
crease in oxygen consumption was not caused by an increase in activity as analysis of
the locomotor activity showed no diﬀerences between the hypothyroid and euthyroid
groups. This is a rather new observation since it is generally accepted that hypothy-
roid rodents and humans exhibit a lower metabolic rate.
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However, recent data have revealed that ambient temperature greatly aﬀects energy
expenditure [159] and that particularly mice studied under conventional animal hous-
ing conditions (i.e., 18-22◦C) are attributed to an unexpected chronic thermal stress
[167]. Under these conditions, the obligatory thermogenesis, that reﬂects the heat
produced during cellular and organ functions in the body, is not suﬃcient to maintain
body temperature, and consequently adaptive thermogenesis is induced. Studies by
C. B. Ueta et al. impressively demonstrated the eﬀects of ambient temperature on
energy expenditure in hypothyroid mice [159]. Only at thermoneutrality (~30◦C) hy-
pothyroid mice exhibited reduced energy expenditure, whereas at room temperature
no diﬀerences were found between hypo- and euthyroid animals. These results are in
line with the ﬁndings by L. P. Klieverik et al. who could not observe any diﬀerences in
resting energy expenditure (REE) at room temperature between hypo- and euthyroid
rats, whereas REE was clearly increased in thyrotoxic rats [96]. Most importantly,
these studies implied that hypothyroidism and thyrotoxicosis are not the mirror im-
age of each other [95]. In view of these data, an upregulation of the metabolic rate
in hypothyroid TRH-R1 ko mice in response to the standard laboratory temperature
(~22◦C) is feasible. This will be a fascinating area for future research involving studies
of hypothyroid TRH-R1 ko mice at cold environments as well as at thermoneutrality.
Since signiﬁcant amounts of BAT have also been detected in humans [168], further
studies are needed to determine whether the obtained data from rodent studies can be
extrapolated to humans and whether such studies might disclose potential therapeutic
strategies to combat obesity.
4.7 Fat Metabolism of TRH-R1 ko Mice
In order to address the inﬂuence of TH levels on the activity of the white adipose
tissue, hypothyroid TRH-R1 ko mice were analysed with respect to the fat amount
and the gene expression of metabolic markers.
Indeed, the computed tomography-based analysis of the fat tissue revealed a reduction
in the amount of visceral and subcutaneous fat in hypothyroid TRH-R1 ko mice com-
pared to euthyroid wild type mice (Fig. 3.9). TH treatment that started at weaning
time was able to normalise fat mass in the mutant mice. Moreover, the ﬁndings of re-
duced fat mass in athyroid Pax8 ko and in wild type mice rendered hypothyroid (Fig.
3.15) conﬁrmed the data obtained in hypothyroid TRH-R1 ko mice. These results
suggest that hypothyroidism is associated with low amounts of fat. The decrease in
adipogenesis and in adipocyte diﬀerentiation, as shown by gene expression analysis,
most likely contributes to the smaller fat depots in these hypothyroid mouse mutants.
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Classically, hyperthyroidism instead of hypothyroidism is linked to a decrease in fat
mass due to an increase in adrenergic-stimulated lipolysis. However, body composi-
tion analysis in several other hypothyroid rodent models have demonstrated reduced
fat mass as well [159, 161, 169]. Studies in mice with a mutation in the TRα gene
(TRα1PV) exhibited a lean phenotype and a signiﬁcant reduction in the mass of white
adipose tissue [169]. The PV mutation in the TRα gene locus resulted in the loss of
T3 binding and thus to the lack of transcriptional capacity of this receptor. Analysis
of the fat metabolism in these mice elucidated a role of this apo-receptor in lipid
homeostasis. The TRα1PV/+ mice exhibited a repressed expression of PPAR-g in the
white adipose tissue at both mRNA and protein levels. Since this transcription factor
has an important function in adipogenesis and fat cell diﬀerentiation, the reduced
PPAR-g expression was linked to the reduction in fat mass in TRα1PV/+ mice. It is
thus tempting to speculate that adipogenesis in TRH-R1 ko mice is aﬀected as well.
In order to analyse the fat metabolism in TRH-R1 ko mice in more detail, the gene
expression of lipogenic and lipolytic enzymes was analysed.
The analysis of lipogenic enzymes in the white fat of hypothyroid TRH-R1 ko mice
revealed reduced mRNA expression of malic enzyme, fatty acid synthase, and acetyl-
CoA carboxylase I compared to wild type and TH-treated mutant mice (Fig. 3.11).
In white fat, TH induce the gene expression of these enzymes, thereby enhancing de
novo lipogenesis [170]. In view of the reduced expression of these genes known to
be positively regulated by T3, one can conclude that this tissue is in a hypothyroid
state and shows reduced lipogenic activity. In addition to the reduced transcript lev-
els of lipogenic enzymes, hypothyroid TRH-R1 ko mice exhibited decreased mRNA
expression of PGC-1a and PPAR-g as well. These proteins are involved in fat cell
diﬀerentiation, hence the decrease in fat content in hypothyroid animals may be par-
tially due to a reduction in fully diﬀerentiated fat cells. In vitro experiments have
demonstrated that PGC-1a and PPAR-g were rapidly induced by T3 administration
both at the mRNA and protein level [171, 172]. The downregulation of those T3-
inducible genes in the white fat of TRH-R1 ko mice further conﬁrms its hypothyroid
state. However, changes in the mRNA expression of the lipolytic enzymes, hormone-
sensitive lipase and adipose triglyceride lipase, were not observed. That the transcript
levels of these lipolytic genes were obviously not altered in hypothyroid TRH-R1 ko
mice does not exclude an impact of the TH status on the protein level. As one example,
TH synergise with the sympathetic nervous system, thereby aﬀecting enzyme activity
in peripheral tissues as it has been described for hormone-sensitive lipase [173]. Thus,
as a future direction, enzymatic activities should be included in the analysis as well.
Therefore, a possible eﬀect of the hypothyroidal state of TRH-R1 ko mice on lipolysis
in the white adipose tissue cannot be excluded.
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4.8 Regulation of Leptin Synthesis and Secretion
One important factor that is released from fat tissue and functions as an aﬀerent
metabolic signal in the central regulation of energy metabolism is leptin [3, 32]. The
discovery of leptin in 1994 [3] opened up a new ﬁeld in obesity research. The inte-
gration of the leptin signal in the brain occurs primarily in the hypothalamus where
it exerts an anorexigenic eﬀect: a decrease in food intake and an increase in energy
expenditure. The physiological role of leptin in energy homeostasis has been under-
lined by the observations that mice and humans with leptin deﬁciency suﬀer from
hyperphagia and severe obesity. Accordingly, correction of leptin deﬁciency by exoge-
nously applied leptin caused a marked reduction in food intake and a normalisation of
the obesity syndrome, an observation that is in line with the concept of a circulating
anorexic factor [32–34].
A positive correlation has been reported between serum leptin levels and fat mass
in rodents and humans [6, 7]. Levels of circulating leptin in humans are elevated in
obesity [5] and decreased in anorexia nervosa [174], thereby reﬂecting the changes in
body fat mass. However, in response to short-term fasting, circulating leptin levels
decreased markedly, a reduction that was out of proportion with the loss of adipose
tissue [175]. Conversely, short-term overeating is associated with increased serum
leptin levels without gaining body weight [176]. Indeed, several short-term energy
signals such as insulin and glucocorticoids have been shown to positively regulate
the expression of leptin mRNA [177, 178]. In contrast, activation of the sympathetic
nervous system was found to suppress leptin expression in mouse adipose tissue [179].
The increase in cyclic AMP production in response to the stimulation of β-adrenergic
receptors in adipose tissue may directly aﬀect leptin mRNA transcription because a
cyclic AMP-responsive element was identiﬁed in the promoter region of the leptin
gene [180]. There is also evidence that leptin serum concentrations depend on gender
and underlie circadian oscillations [181]. Much higher leptin levels have been detected
in females than in males, regardless of the fat mass. Leptin levels were highest be-
tween midnight and the early-morning hours and lowest levels appeared around noon
to mid-afternoon.
Leptin Synthesis in TRH-R1 ko Mice
In light of the prominent function of leptin in regulating body weight and appetite,
an interaction between TH and leptin has been suggested. Indeed, the paraventricu-
lar hypothalamic TRH neurons represent an important target for peripheral energy
signals such as leptin which are centrally integrated in order to adjust the activity
of the hypothalamic-pituitary-thyroid (HPT) axis to the peripheral energy state. As
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one example, a fasting-induced downregulation of TRH expression and a consecutive
drop in serum TH levels can be prevented by leptin administration indicating that
leptin exhibits a strong dominant eﬀect on the HPT axis. However, less convincing
information is available with regard to the question whether TH in turn can regulate
leptin expression as well. In order to evaluate the putative eﬀects of TH on leptin
expression, hypothyroid mice were studied with regard to leptin gene expression in
fat tissue and serum leptin levels.
In all studied hypothyroid animal models (TRH-R1 ko, Pax8 ko, and hypothyroid WT
mice), circulating leptin levels were found to be decreased (Fig. 3.12 and 3.16) which
is not such a surprising ﬁnding in light of the reduced fat mass in these animals. In
addition, relative transcript levels for leptin were found to be decreased under hypothy-
roid conditions as well, suggesting that TH aﬀect leptin expression either directly or
indirectly. In order to elucidate the underlying mechanisms, cell culture experiments
were performed. 3T3-L1 adipocytes were treated with T3 and analysed with regard
to leptin mRNA levels. In agreement with the data published by T. Yoshida et al.
[182], the analysis revealed an increase in leptin mRNA levels after 6 h and 12 h of T3
stimulation (Fig. 3.17). These results thus suggest a possible direct eﬀect of TH on
leptin gene expression, though in the leptin promoter a responsive element for TH has
not yet been reported. Therefore, indirect eﬀects of TH on leptin expression cannot
be excluded.
Thyroid Hormones and Leptin Synthesis
This study indicates that TH positively regulate leptin synthesis in mice. Both, the
TH-induced leptin expression in adipose tissue and the TH-dependent modulation of
fat mass contribute to the circulating leptin levels in the serum. The data suggest
an adaptation of the serum leptin levels to the circulating TH concentrations rather
than a compensatory mechanism. In line with this concept are observations made in
animals in response to fasting or overfeeding. Fasting was shown to induce a downreg-
ulation of the HPT axis and subsequently a fall in circulating TH levels, a mechanism
presumed to serve energy stores [183, 184]. Interestingly, circulating leptin levels were
also found to be reduced in response to food deprivation [175]. Conversely, overfeeding
has been shown to cause an increase in leptin levels and moderately elevated TSH and
TH levels [176, 185]. In support of the hypothesis that the HPT axis inﬂuences leptin
expression in a positive manner are the ﬁndings that TSH stimulates leptin secretion
by a direct eﬀect on adipocytes [186].
In other species, divergent eﬀects of TH on leptin expression have been noted. In
hypothyroid rats, a raise in leptin mRNA levels and increased leptin release from
adipocytes were reported [187]. Moreover, in vivo studies in rats demonstrated that
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administration of thyrotoxic doses of T3 induced a decrease in plasma leptin levels
which was followed by pronounced hyperphagia [126]. Based on these ﬁndings, TH
were suggested to decrease serum leptin concentrations by downregulation of leptin
gene expression in adipose tissue [188] or indirectly by the regulation of fat mass [189].
Studying leptin expression in humans again revealed diﬀerent results. Decreased lep-
tin levels have been found in hypothyroid patients when compared to control subjects
matched for age, sex, and body mass index [190]. Thus, species diﬀerences in the reg-
ulation of leptin expression cannot be excluded. Since mouse mutants are frequently
used to study central circuits of appetite and body weight regulation, it appears to be
of utmost importance to take into account how leptin production and signalling are
regulated by TH in mice, though the exact mechanisms remain to be elucidated.
4.9 Thyroidal State of the Hypothalamus in
TRH-R1 ko Mice
In the past, the eﬀects of TH in the regulation of energy homeostasis have been at-
tributed to peripheral actions. In more recent years, substantial evidence from genetic
and molecular biology studies demonstrated important eﬀects of TH in the CNS as
well. TH receptors have been shown to be expressed in a number of hypothalamic
nuclei, including the ARC and the PVN, suggesting an interplay between central TH
signalling and the regulation of energy metabolism [115–117].
The attempt of this study was to analyse the thyroidal state of the hypothalamus in
hypothyroid TRH-R1 ko mice compared to euthyroid controls. For this purpose, the
concentrations of T3 and T4 were determined in pools of ﬁve dissected hypothalami
per group and revealed reduced T3 and T4 concentrations in TRH-R1 ko mice com-
pared to wild type animals (Fig. 3.19). Moreover, hypothalamic mRNA expression
of deiodinase type 2 (DIO2) was analysed to get further information with regard to
the local thyroidal state. In line with the decreased TH levels, DIO2 was found to
be increased (Fig. 3.18) further indicating a hypothyroidal state of this brain area.
The upregulation of DIO2 was most likely a direct consequence of the low TH levels
since TH treatment of hypothyroid TRH-R1 ko mice led to a normalisation of the
expression levels. In contrast to the situation observed in the BAT, increased DIO2
expression in the hypothalamus was not suﬃcient to completely upregulate local T3
concentrations. Consequently, the hypothalamus of TRH-R1 mouse mutants is in a
hypothyroid state.
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4.10 Central Leptin Signalling in TRH-R1 ko
Mice
As a hypothyroid condition in the hypothalamus may change the central sensing of
peripheral energy signals, the regulation of the leptin signalling pathway in the CNS
of hypothyroid mice was further investigated. For this purpose, transcript levels of
the leptin receptor (Ob-R) and of the suppressor of cytokine signalling 3 (SOCS3)
were analysed in the hypothalamus by radioactive in situ hybridisation.
The ISH results revealed markedly increased Ob-R and reduced SOCS3 mRNA ex-
pression in hypothyroid TRH-R1 ko mice compared to euthyroid wild type animals,
whereas TH-treated TRH-R1 ko mice did not show any alterations (Fig. 3.23). Sim-
ilarly, Pax8 ko mice exhibited an increase in Ob-R and a decrease in SOCS3 mRNA
expression. These data indicate that the thyroidal state of mice aﬀects the expression
of hypothalamic Ob-R and SOCS3.
However, in addition to the reduced hypothalamic TH levels, TRH-R1 ko (and Pax8
ko) mice exhibited decreased serum leptin levels as well. Therefore, it could be pos-
sible that the observed changes in Ob-R and SOCS3 expression in TRH-R1 ko and
Pax8 ko mice are a consequence of the low leptin levels and not a direct consequence
of the changes in the TH status. The latter hypothesis is supported by several stud-
ies in rodents that showed a positive regulation of hypothalamic Ob-R expression by
leptin. Rats with diet-induced obesity exhibited hyperleptinemia in combination with
reduced levels of Ob-R gene expression in the hypothalamus [191, 192]. Conversely,
fasting has been shown to be associated not only with decreased leptin levels, but
also with increased Ob-R expression in the hypothalamic arcuate nucleus (ARC) and
the ventromedial hypothalamus (VMH) of rats [193]. Similar results were obtained in
mice and regulation of hypothalamic Ob-R gene expression by both leptin levels and
nutritional state has been suggested [194]. In ob/ob mice, that lack circulating leptin,
an upregulation in Ob-R gene expression in the hypothalamic ARC and VMH has
been detected, while leptin challenge has been reported to downregulate expression
in the ARC [195]. These ﬁndings, together with the known regulation of SOCS3 by
leptin [61], may explain the increased Ob-R and the decreased SOCS3 mRNA expres-
sion levels in the hypothalamus of mice with low serum leptin levels such as TRH-R1
ko and Pax8 ko mice.
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4.11 Central Leptin Signalling in TRH-R1/ob dko
Mice
In order to investigate whether the changes in Ob-R and SOCS3 expression in hy-
pothyroid mice were attributed to the low serum leptin or the low TH levels, TRH-R1
ko mice were crossed with leptin-deﬁcient ob/ob mice. The resulting leptin-deﬁcient
and hypothyroid TRH-R1/ob double knockout (R1/ob dko) mice and the euthyroid
ob/ob mice were peripherally injected with equal amounts of leptin. The mRNA ex-
pression of the Ob-R and SOCS3 were analysed by ISH. Additionally, the ISH results
were validated by laser-capture microdissection combined with quantitative real-time
PCR.
Upon leptin treatment, hypothalamic Ob-R mRNA expression was increased and
SOCS3 mRNA levels were decreased in the hypothyroid R1/ob dko mice compared to
euthyroid ob/ob mice (Fig. 3.24). The diﬀerences in gene expression were speciﬁcally
prominent in the hypothalamic ARC, which was further conﬁrmed by quantitative
real-time PCR. These results thus suggest that TH, in addition to leptin, inﬂuences
the expression of Ob-R and SOCS3 in the ARC neurons of mice. These ﬁndings are
in agreement with the demonstration that T3 decreased the expression of Ob-R in
cultures of hypothalamic neurons derived from chickens [196].
Of note, the gene expression analysis of the diﬀerent Ob-R isoforms in the ARC re-
vealed an increase only in the short isoforms, Ob-Ra and Ob-Rc, in leptin-treated
R1/ob dko mice compared to leptin-injected ob/ob mice, whereas the long form, Ob-
Rb, was not aﬀected (Fig. 3.25). Alternative mRNA splicing produces ﬁve diﬀerent
leptin receptor isoforms (Ob-Ra-e) in mice [41]. The short isoform, Ob-Ra, is pre-
dominantly expressed in the choroid plexus and microvessels and may play a role
in leptin uptake or eﬄux from the CSF and in the receptor-mediated transport of
leptin across the BBB into the brain [44, 45]. The physiological role of the other
short membrane-bound isoforms, Ob-Rc and Ob-Rd, is largely unknown. In view of
the increased expression of the short leptin receptor isoforms, Ob-Ra and Ob-Rc, in
R1/ob dko mice one can assume that the transport of leptin into the CNS might be
aﬀected (see also section 4.13).
The leptin receptor signalling pathway in R1/ob dko mice might additionally be in-
ﬂuenced as a consequence of the decreased SOCS3 expression (Fig. 3.25). SOCS pro-
teins are negative regulators of several cytokine signalling systems, including those of
interleukin-6, leukemia-inhibitory factor and erythropoietin [197]. Since the Ob-Rb
belongs to the cytokine receptor superfamily, it was likely that SOCS3 functions as
an intracellular negative feedback loop, thereby inhibiting leptin signalling. Indeed,
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SOCS3 contributes to the attenuation of Ob-R signalling by masking phosphotyrosine
residues of the leptin receptor and of the catalytic region of the Janus kinase [58–61].
The leanness and enhanced leptin sensitivity of mice lacking SOCS3 in the CNS fur-
ther supports the concept that SOCS3 limits Ob-Rb action in vivo [198]. Thus, one
can speculate that the decrease in SOCS3 expression in hypothyroid R1/ob dko mice
positively inﬂuences the hypothalamic leptin signalling pathway.
4.12 Response to Leptin of TRH-R1/ob dko Mice
Eﬀect on Food Intake and Body Weight
In the present study, the question whether the metabolic response to leptin treatment
is altered under hypothyroid conditions was analysed. The hypothyroid R1/ob dko
mice and the euthyroid ob/ob animals were injected twice daily with recombinant
leptin for three days. During the time of leptin treatment and ﬁve additional days of
leptin withdrawal, the suppression of food intake and the decrease in body weight were
determined. Remarkably, hypothyroid R1/ob dko mice exhibited reduced suppression
of food intake and reduced loss of body weight in response to leptin administration
compared to euthyroid ob/ob animals (Fig. 3.28). In order to substantiate these
ﬁndings, ob/ob mice were rendered hypothyroid by MMI treatment and the response
to leptin was analysed as well. The hypothyroid ob/ob mice showed a similar reduced
response to leptin treatment as R1/ob dko mice with regard to food intake and body
weight. Overall, these data indicate an impaired sensing of the leptin signal under
hypothyroid conditions.
Eﬀect on the Activation of Stat3
The major leptin signalling pathway implicated in neural control of energy balance is
the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3)
pathway [50–52]. Leptin binding to Ob-Rb activates the constitutively receptor-
associated Janus kinases to mediate receptor tyrosine (Y1138) phosphorylation. Upon
recruitment and tyrosine (Y705) phosphorylation of STAT3, activated STAT3 translo-
cates to the nucleus. There, it promotes transcriptional regulation of target genes. In
view of the diminished response to leptin in the hypothyroid R1/ob dko mice, the
protein levels for phosphorylated Stat3 (phospho-Stat3) in the hypothalamus were
analysed. Accordingly, upon leptin injection phospho-Stat3 was much less pronounced
in the ARC of hypothyroid R1/ob dko compared to ob/ob mice receiving the same
treatment, indicating an overall reduced leptin signalling in these animals (Fig. 3.26).
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To verify the impact of the thyroidal state on the phospho-Stat3 levels, the leptin re-
sponse in ob/ob mice that were rendered hypothyroid by MMI treatment was tested
as well. Again, reduced phospho-Stat3 levels in the ARC of hypothyroid-rendered
ob/ob mice were detected (Fig. 3.27). These data demonstrate that the diminished
metabolic response to leptin under hypothyroid conditions is reﬂected by markedly re-
duced phospho-Stat3 protein levels in the hypothalamus. This reduced responsiveness
to exogenous leptin in hypothyroid mice has given rise to the idea that hypothyroidism
is associated with a state of relative leptin resistance (see section 4.13).
Eﬀect on Neuropeptide Expression
In light of the well-established regulation of AgRP and POMC by leptin, the gene
expression of these neuropeptides in response to leptin was analysed in hypothyroid
mice and euthyroid controls by ISH and quantitative real-time PCR.
Unexpectedly, no diﬀerences in POMC and AgRP mRNA expression were found
between the hypothyroid R1/ob dko mice and the euthyroid ob/ob animals upon
leptin treatment (Fig. 3.30 and 3.31). However, in view of the markedly reduced
phospho-Stat3 signals in the hypothyroid R1/ob dko mice, one would have expected
a consequence on Stat3 targets such as POMC and AgRP. It has been shown that
NPY/AgRP- as well as POMC-containing neurons express the long-form leptin re-
ceptor, Ob-Rb [37, 46, 47]. Leptin signalling stimulates the synthesis of POMC and
promotes the ﬁring rate of POMC neurons, whereas the expression of AgRP is sup-
pressed by leptin [37, 199]. The deletion of the Ob-Rb from NPY/AgRP and/or
POMC neurons in mice results in weight gain [48, 49]. Conversely, the restoration of
leptin signalling in the ARC of mice lacking the Ob-Rb decreased body weight and
food intake [200].
However, it is likely that the posttranslational processing of the neuropeptide precur-
sor POMC by prohormone convertases is aﬀected by the thyroid status of the mice
since TH have been demonstrated to regulate prohormone convertase gene expression
in the pituitary and hypothalamus [201, 202]. It is thus feasible that hypothala-
mic POMC processing is aﬀected in hypothyroid mice. Consequently, altered levels
of the POMC-derived peptide, α-MSH, might modulate downstream signalling and
consequently the regulation of appetite. To which extent the melanocortinergic sig-
nalling pathway triggers the metabolic response to leptin in hypothyroidism needs to
be analysed in future experiments. The ﬁnding that Stat3 deletion speciﬁcally from
NPY/AgRP arcuate neurons did not aﬀect AgRP mRNA levels [203] supports the
hypothesis that the alterations in leptin signalling in hypothyroid mice are not neces-
sarily mediated by AgRP. Of note, other hypothalamic neuropeptides such as cocaine
and amphetamine-related transcript (CART) and neurotensin (NT) have been shown
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to be induced by leptin and to mediate the central eﬀects of leptin on food intake
[204, 205]. In future studies it will be of major interest to delineate the potential
role of other, maybe yet unidentiﬁed, leptin targets in the regulation of central leptin
signalling under hypothyroid conditions.
4.13 Mechanisms Underlying Leptin Resistance in
Hypothyroidism
Leptin resistance is mainly associated with obesity, a state of elevated circulating lep-
tin levels as a consequence of large fat mass. Most obese individuals do not adequately
respond to increased leptin levels with reduced food intake [6]. Moreover, the ability
of leptin to activate hypothalamic signalling is markedly diminished in diet-induced
obesity [206]. The underlying mechanisms of leptin resistance remain still a matter of
debate. The two theories that received most attention propose a failure of circulating
leptin to reach its targets in the brain and inhibition of the intracellular signalling
cascade [56].
Impaired Leptin Transport into the CNS
Indeed, a saturable transport system has been described for leptin to cross the BBB
and evidence exists for a defective BBB transport of leptin in obesity [57]. Short
leptin receptor isoforms such as Ob-Ra are implicated to play a role in the receptor-
mediated transport of leptin across the BBB into the brain due to their high expression
in microvessels [44, 45]. In this study, however, increased mRNA expression levels
for the short isoforms, Ob-Ra and Ob-Rc, were found in the ARC of hypothyroid
R1/ob dko mice compared to euthyroid ob/ob animals after leptin treatment (Fig.
3.25). This might suggest that the transport of leptin is even favoured in hypothyroid
animals and does not explain their leptin resistance. However, the hypothalamic
ARC resides at the most ventral part of the third ventricle in close contact with the
median eminence which has an incomplete BBB [12]. Due to its close location to the
median eminence, it is not clear to which extent the leptin transport across the BBB
contributes to leptin action in ARC neurons. Therefore, defects in the intracellular
signalling cascade, as observed by the reduced phospho-Stat3 levels, might play a
more important role than leptin transport.
Inhibition of the Intracellular Signalling Cascade by SOCS3
For SOCS3, a potential role for a negative feedback of the central leptin signalling path-
way has been described. SOCS3 can bind to phosphotyrosine residues on the Ob-Rb
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to mediate inhibition of STAT3 signalling [58]. In addition, SOCS3 can mask cat-
alytic regions of the Janus kinase 2, thereby repressing downstream signalling [59, 60].
Using cultured cells, a repression of Ob-Rb signalling by SOCS3 overexpression was
demonstrated, whereas RNAi-mediated knockdown of SOCS3 resulted in an increased
Ob-Rb signalling [60]. High levels of leptin can induce the transcription of SOCS3
via activation of the JAK2/STAT3 pathway. Hence, increased hypothalamic SOCS3
expression in several rodent models of leptin-resistant obesity has been observed. This
ﬁnding is in line with a potential role of SOCS3 in leptin resistance [61].
In the present study, the mRNA expression of SOCS3 was analysed in hypothyroid
mice by ISH and validated by quantitative real-time PCR. Interestingly, reduced hy-
pothalamic SOCS3 mRNA expression was detected in the leptin-resistant hypothyroid
R1/ob dko mice compared to the euthyroid ob/ob mice after leptin treatment (Fig.
3.24 and 3.25). In contrast to obese and leptin-resistant individuals that exhibit long-
lasting high circulating leptin levels, the R1/ob dko and ob/ob mice have never been
exposed to leptin before. The ﬁnding that in response to short-term leptin stimula-
tion, SOCS3 expression is decreased in the hypothyroid and leptin-deﬁcient mice is
in line with the overall reduced response to leptin in these mice.
Inhibition of the Intracellular Signalling Cascade by PTPN1
The protein tyrosine phosphatase type 1 (PTPN1) has recently been implicated in
attenuating leptin signalling via a direct dephosphorylation of the Janus kinase 2
[62–64]. Expression of PTPN1 is found in the hypothalamus, where it is highly en-
riched in the ARC. Mice with POMC neuron-speciﬁc deletion of PTPN1 exhibited
an enhanced leptin sensitivity and were protected against diet-induced obesity [207].
Increased hypothalamic PTPN1 mRNA and protein levels have been reported during
high-fat diet induced leptin resistance [65]. In addition to leptin-dependent mecha-
nisms, a leptin-independent regulation of hypothalamic PTPN1 expression has been
suggested as well.
In this study, hypothalamic PTPN1 mRNA expression was analysed in hypothyroid
mice by ISH and validated by quantitative real-time PCR. However, no diﬀerences in
PTPN1 mRNA levels between hypothyroid R1/ob mice and euthyroid ob/ob animals
were detected following leptin treatment (Fig. 3.32). Moreover, neither in R1/ob dko
nor in ob/ob mice a prominent eﬀect of leptin treatment on PTPN1 expression was
observed. In contrast to these data, a study with leptin-deﬁcient ob/ob mice infused
with leptin showed a signiﬁcant increase in hypothalamic PTPN1 mRNA levels [65].
Of note, these mice were chronically infused with leptin via an osmotic minipump for
14 days. In contrast, the mice tested in this study received leptin twice daily only
for three days. From the obtained gene expression data in R1/ob dko mice, hypotha-
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lamic PTPN1 is obviously not involved in the regulation of central leptin signalling
in hypothyroid mice. However, it is not known whether long-term leptin treatment
would aﬀect PTPN1 expression and whether PTPN1 activity is regulated in hypothy-
roidism. Thus, it is conceivable that an altered activity of PTPN1 under hypothyroid
conditions might contribute to the diminished response to leptin treatment.
Taken together, TRH-R1 ko mice exhibit metabolic abnormalities which are mainly
controlled by the TH status of the mice. The absence of TRH-R1 alone does not
appear to have a detectable impact on the energy metabolism since TH-treated TRH-
R1 ko mice did not show any signiﬁcant metabolic diﬀerences compared to wild type
animals. The analysis of TRH-R1 ko mice revealed that hypothyroidism is not neces-
sarily connected to reduced metabolic rate and increased body weight. Instead of that,
a decrease in peripheral TH concentrations might even favour an increase in energy
expenditure and consequently a reduction in body weight. The studies of TRH-R1
ko mice also uncovered novel mechanisms by which TH inﬂuence energy metabolism.
On the one hand, hypothyroidism in mice might aﬀect the production of peripheral
energy signals as demonstrated in this thesis for the adipose tissue-derived hormone
leptin. The analysis of three diﬀerent mouse models of hypothyroidism revealed that
leptin production in hypothyroid mice is impaired. On the other hand, the central
processing of such peripheral energy signals might be aﬀected as well. The metabolic
response to leptin was strongly diminished in the hypothyroid and leptin-deﬁcient mice
compared to the euthyroid and leptin-deﬁcient animals suggesting a state of relative
leptin resistance in hypothyroidism. As the hypothalamic TH concentrations in hy-
pothyroid mice are decreased, a possible interference with the central leptin signalling
pathway was concluded and validated by the reduced hypothalamic Stat3 activation
in response to leptin. At present, the underlying mechanisms for the hypothalamic
leptin resistance in hypothyroid mice remain elusive. Further elucidation of the cen-
tral eﬀects of TH on leptin sensing and signalling will add to our understanding of
how the thyroidal state contributes to central leptin resistance.
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